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editorial
I was a mere babe-in-arms when my parents dragged my 
brothers and me across an ocean and most of a continent to 
settle in Canada. Once, being an immigrant meant staring 
open-mouthed at the ESL teacher and mailing birthday 
cards that took three months to arrive. Now, it means 
heated, multilingual video-debating with relatives half a 
world away as all involved watch the same live newscast 
about events in a third place altogether.
With continual improvements in the affordability 
and convenience of international travel, trade, and 
information exchange, stories like mine are becoming 
more commonplace and monikers like “global village” are 
becoming increasingly apt for describing the world. Modern 
telecommunications and transport are progressively 
overcoming the challenges posed by physical separation, 
bringing the rest of the world quite literally closer to home. 
Still, geography continues to matter and stories vastly 
unlike mine remain the norm. The International 
Telecommunications Union estimates, for example, that 77% 
of the developed world is connected to the Internet while only 
31% of the developing world can say the same. Accordingly, 
the WHO finds that low income countries contend with 
twice the number of disability-adjusted life-years per capita 
than high income countries do. Clearly, people and ideas 
might be moving faster, but they’re not reaching many parts 
of the world that are in need. In this issue of the UWOMJ, 
we explore some of the causes and consequences of these 
disparities, both in Canada and abroad.
Some of our contributors, inspired by personal interest and 
experiences abroad, choose to explore the challenges of 
medical provision in locales and through systems different 
from our own. These run the gamut from the everyday 
headaches of providing safe and cost-effective nutrition, 
surgery, and diagnostics to the difficulties of managing once-
in-a-lifetime infectious disease or natural disaster crises. 
Other contributors discuss the proper way to manage 
Canadian healthcare, given its global context. 
Overwhelmingly, the message is that one size does not 
fit all: refugees and other newcomers are deserving 
and in need of aid, and complementary and alternative 
medicines popularized by cultural practices merit 
individual consideration.
The stories told in this issue hail from all over the world, 
many in places far from here, but as Sting would have us 
know, that all “gets a little closer every day.” The health 
and well-being of those living on the other side of the 
world do and should matter to us. So, for less than the 
price of a bus fare to the airport, let the UWOMJ take you 
on a highlights tour of the global healthcare landscape.
Anthony Chow
Senior Associate Editor
One World (Not Three)
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abstract
Complementary and alternative medicine (CAM) is widely 
used in Canada and throughout the world, making it inevita-
ble that family physicians will encounter CAM use in their pa-
tients. CAM therapies are highly variable and are not subject 
to regulation or oversight, making some such modalities poten-
tially dangerous. Presently, CAM use is discussed during stan-
dard history taking, but the information gathered may be of 
limited utility due to the wide variety of CAM that exists; such 
diversity makes it practically impossible for one physician to 
know the risks associated with each CAM. Additionally, some 
CAM may not identified as such by the patient (eg chiroprac-
tic) and may not be reported during a standard patient inter-
view. There currently exists no standardized method of collect-
ing a patient’s history of CAM use, or for assessing risk based 
on the information collected. Here, we present a clinical tool 
that helps to screen for use of CAM and stratify patients into 
risk categories accordingly. It also makes suggestions for man-
agement and follow-up of these patients according to their risk 
category. Included are several quick reference tables to enable 
physicians to rapidly stratify patients into an appropriate cat-
egory. This test may help to screen patients for CAM use that 
puts their health at risk, thereby increasing detection, and en-
abling timely intervention by the physician to prevent adverse 
events due to CAM use.
background
Complementary and alternative medicine (CAM) is defined by 
the Canadian Medical Association and United States National In-
stitutes of Health as “a group of diverse medical and health care 
systems, practices, and products that are not presently considered 
to be part of conventional medicine.” For this reason, they are not 
subject to the same standards of scientific scrutiny that convention-
al therapies are, and consequently, many are of questionable legit-
imacy and safety.1 Regardless, several surveys done over the past 
20 years have consistently indicated that 70% to 75% of Canadians 
have used CAM at least once in their lifetime.2-4 Despite the high 
prevalence of CAM use in the Canadian population and its ability 
to affect the health and safety of a patient, it can go unaddressed or 
undisclosed in the family physician’s clinic.5
CAM can be most usefully divided into three categories: prod-
ucts, interventions, and practitioners. Products include items typ-
ically bought by consumers, such as herbal teas and remedies, vi-
tamins and minerals, homeopathic remedies, traditional Chinese 
medicines (TCM), and many others. Interventions refer to practic-
es such as spinal manipulation, electromagnetic field therapy, crys-
tal healing, and others which may or may not involve a practitioner. 
Practitioners are individuals who market themselves as care pro-
viders in particular fields, such as chiropractic, TCM, homeopathy, 
naturopathy, Ayurveda, acupuncture, and others. Practitioners may 
or may not prescribe or provide both products and interventions.1
cause for concern
While some regulatory bodies exist for mainstream therapies, 
CAM is poorly regulated overall.6-8 Due to poor regulation and the 
lack of medical education of most practitioners, CAM can pose 
significant threats to the health of Canadians through a variety of 
mechanisms: 
•	 The traditional Chinese herb ma huang contains unregulated 
levels of ephedrine and can cause numerous adverse effects 
including palpitations, hypertension, arrhythmia, nervousness, 
tremors, seizures, heart attack, stroke, and death.9
•	 Ginseng is a naturopathic remedy marketed under the name 
COLD-FX as an immune system booster that will prevent viral 
influenza and strengthen normal body function, among other 
such claims. Serious drug interactions with warfarin have been 
described, as well as stimulation of manic episodes in psychiat-
ric patients on antidepressants.10
•	 Ayurvedic medicine is a form of traditional Indian medicine 
that stresses the use of plant-based therapies, yet Ayurvedic 
medicines have been shown to contain toxic levels of heavy 
metals; one study found that one in five Ayurvedic herbal med-
icine products contained potentially harmful levels of lead, 
mercury, or arsenic.11
•	 Chiropractic is an intervention which focuses on spinal ma-
nipulation therapy, often marketed as a panacea, but numerous 
serious adverse effects have been reported as a result of chi-
ropractic manipulation, including stroke, neuropraxic injury, 
epidural hematoma, paraplegia, and fatal posterior circulation 
cerebrovascular accident.12-15
•	 Acupuncture is a component of some TCM and involves punc-
turing a patient’s skin with needles along so-called meridian 
lines to achieve therapeutic effect. Numerous systematic re-
views, multi-centre trials, and prospective studies have high-
lighted the dangers of acupuncture, finding that it can cause 
pneumothorax, hepatitis C, septicemia, endocarditis, local skin 
infection, perichondritis, arthritis, osteomyelitis, and many less 
serious side effects such as hematoma, slight hemorrhage, and 
dizziness.16-20
A clinical tool for evaluating complementary 
and alternative medicine utilization and risk
Keegan Guidolin (Meds 2017), Mackenzie Drew (BSc Cand)
Faculty Reviewer:  Dr Michael Craig, MD, CCFP (Department of Family Medicine)
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This represents a brief illustration of the dangers posed by CAM 
therapies. Of course, all medical therapies carry some risk; however, 
in the cases of most CAM, no benefit has been shown via randomized 
controlled trial, making the risk-benefit calculation one-sided.21
Not all CAM poses a direct threat to health. CAM is a catch-all 
term which should be parsed for clarity: complementary medicine 
is unconventional therapy used concurrently with conventional 
therapy, while alternative therapy is unconventional therapy used 
exclusively, in place of conventional therapy. This is an important 
distinction because an individual using alternative medicine is, by 
definition, foregoing conventional treatment — this poses an entire-
ly different threat.22 CAM such as homeopathy, crystal healing, and 
reiki poses no direct threat, but may prevent people from seeking 
appropriate medical attention.
the cam risk assessment tool
Numerous studies involving CAM have highlighted the need 
for a better method of assessing, following, and managing CAM-us-
ing patients.21 Here we present a clinical tool intended for use by 
the family physician, or any physician following a patient for an 
extended period of time. This tool represents a means of assessing 
patients’ use of CAM and risk of associated harm, and classifies pa-
tients into categories with targeted indications for follow-up. This 
tool is designed to be used when taking the initial patient history 
for a new patient in a family practice, but may be implemented at 
any time. 
The tool itself consists of three components: (1) a set of initial 
questions to determine whether or not the patient uses CAM (CAM 
determination), (2) a set of questions to determine the qualitative po-
tential for harm as a result of CAM use, and (3) a set of questions to 
determine whether the patient uses CAM exclusively (alternatively) 
or alongside conventional medicine (complementarily). These ques-
tion sets help to quickly and easily stratify patients into risk catego-
ries (Figure). Each question set is aimed at evaluating the use of CAM 
from each of the three categories (products, interventions, and prac-
titioners). These questions are meant only to screen for CAM which 
the patient may not consider outside of conventional medical care. 
For example, patients may consider chiropractic manipulation con-
Figure: CAM risk assessment tool.
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ventional medical treatment when a physician asks. The questions 
are not meant to be exhaustive and follow-up questions are necessary 
for an adequate assessment of CAM use.
Included is a patient scoring system and score-dependent 
management recommendations (Table 1). These should be taken 
only as a list of options to consider based on the relative risk. They 
are not meant to be exhaustive, nor are they meant to be applied to 
every patient—naturally, the physician must apply the entirety of 
this tool on a case-by-case basis. To help simplify the application of 
the tool, two Quick Reference Charts are included. The first is a list 
of types of CAM practitioners; patients who identify any of these 
practitioners as someone they regularly see for health advice can 
be considered to use CAM (Table 2). The second is a list of CAM 
modalities stratified into likely harmless and potentially harmful 
categories based on literature review (Table 3). The use of this table 
helps to determine a patient’s risk of harm (CAM class I vs II).
The ultimate goal of the management considerations presented 
by this tool is the reduction and eventual elimination of CAM use by 
the patient. This is theoretically achieved over multiple visits, with 
CAM score reassessment at each; however, particular care should 
be taken in a few situations. Firstly, in cases of CAM class B, or use 
of alternative medicine, care must be taken to avoid confrontation. 
Since these patients use CAM as an alternative, their trust in main-
stream medicine may be tenuous, and thus, if a physician addresses 
CAM use too aggressively, patient trust may be lost and the patient 
may be lost to follow-up. Secondly, special attention should be given 
if a child is being treated with CAM, particularly CAM class II (po-
class management considerations
CAM 0 (No CAM) •	 Repeat screen at periodic health assessment (PHA).
CAM IA 
•	Complementary
•	Likely harmless
•	 Education regarding lack of evidence for CAM.
•	 Encourage physician consultation before starting new therapies.
•	 Contact CAM practitioner, open communications regarding treatment prescribed.
•	 Works towards dispelling CAM use, move patient towards CAM class 0. 
•	 Re-evaluate at PHA.
CAM IB
•	Alternative
•	Likely harmless
•	 Non-aggressive discussion recommended — trust in mainstream medicine and physicians may be tenuous.
•	 Gain patient trust.
•	 Work towards a CAM class IA designation before addressing lack of evidence for CAM.
•	 Contact CAM practitioner, open communications regarding treatment prescribed.
•	 Address immediate health concerns at physician’s discretion.
•	 Follow patient closely.
CAM IIA
•	Complementary
•	Potentially harmful
•	 Education regarding lack of evidence for CAM.
•	 Encourage physician consultation before starting new therapies.
•	 Contact CAM practitioner, open communications regarding treatment prescribed.
•	 Address harmful effects of CAM (eg heavy metal screen in Ayurveda use).
•	 Advise against use of harmful CAM.
•	 Pediatric: Refer to Children’s Aid Society (or analogue) at physician’s discretion.
CAM IIA 
•	Alternative
•	Potentially harmful
•	 Non-aggressive discussion recommended  — trust in mainstream medicine and physicians may be tenuous.
•	 Address immediate health concerns.
•	 Gain patient trust.
•	 Work towards CAM class IIA initially.
•	 Contact CAM practitioner, open communications regarding treatment prescribed.
•	 Advise against use of harmful CAM only if patient is open to the idea.
•	 Pediatric: Refer to Children’s Aid Society (or analogue) at physician’s discretion.
Table 1: Summary and Indications: Class Definitions and Corresponding Management Considerations
Table 2: Practitioner Quick Reference: List of CAM Practitionersa
Acupuncturist Homeopathic doctor
Aromatherapist Naturopath/Herbalist
Astrologer Osteopathic doctor
Chiropractor Reflexologist
Crystal Healer Shaman
Holistic doctor Traditional Chinese medical doctor
a Self-identified as CAM practitioners in survey and promotional publications.22,23
Table 3: Harm Quick Reference: Likely Harm Associated with Complementary 
Use of Common CAM
Likely harmlessa •	 Acupressure/shiatsu24
•	 Faith healing/prayer25
•	 Hypnosis26
•	 Magnetic healing27
•	 Reiki/therapeutic touch28
Potentially harmfulb •	 Acupuncture16-20
•	 Ayurvedic medicine11
•	 Chiropractic12-15
•	 Colonics29
•	 Herbal supplementationc,10,30
•	 Homeopathic medicine31
•	 Traditional Chinese medicine9,32
a Harmlessness is not an endorsement of CAM effectiveness.
b Harm classification based on complementation of conventional care; alternative care has 
inherent risks.
c Unregulated or poorly regulated.
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tentially harmful CAM). Continued use of potentially harmful CAM 
on pediatric patients in the face of physician advice to the contrary 
raises serious concerns regarding abuse, and the involvement of 
the Children’s Aid Society and analogous groups may be indicat-
ed. Ultimately, follow-up is key in both of these scenarios, as the 
patient-physician relationship should be developed and leveraged 
appropriately to ensure the health of patients who use CAM. 
limitations and future directions
The relative lack of existing research on the consideration of 
CAM as a risk factor for future medical conditions makes a tool like 
the one presented here inherently qualitative in nature. It is diffi-
cult to make empirical risk evaluations or evaluate the effect of the 
management considerations listed here in a quantitative fashion. As 
such, this tool is presented as a means of standardizing the CAM 
component of a patient history in order to act as a screen. Primar-
ily, this tool aims to help physicians take a more complete history 
with regard to CAM use in their patients. Future studies may assess 
whether the use of this tool increases detection of CAM use in pa-
tients at the level of the primary caregiver.
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Surgical hygiene  
Refining the WHO Safe Surgery Saves Lives guidelines 
Alexander Levit (Meds 2017), Denise Darmawikarta (Meds 2016)
Faculty Reviewer: Dr Javeed Sukhera, MD (Department of Psychiatry, Office of Global Health)
clinical procedures
abstract
Overwhelming rates of postsurgical adverse outcomes have 
been recognized to be preventable. As a means of minimizing the 
incidence of iatrogenesis, in 2005 the World Health Organization 
(WHO) launched the Clean Care is Safer Care campaign, which 
focused on the importance of hand hygiene. Following its success, 
the WHO hoped to utilize similar strategies in their Safe Surgery 
Saves Lives campaign, which began in 2007. Despite active efforts 
to implement the associated 19-step surgical checklist, resource 
limitations restrict the full potential of such harm reduction strat-
egies. Here, we discuss current evidence evaluating the effective-
ness of the WHO’s surgical checklist and address challenges with 
respect to its application in the real world.
introduction
Iatrogenic injury, inadvertent harm or illness caused by medi-
cal therapy, remains a significant issue due to its impacts on patient 
outcomes and physician practice. To address the persistently high 
incidence of iatrogenesis, the World Health Organization (WHO) 
passed a resolution in 2002 that identified patient safety as a glob-
al priority. This prompted a series of internationally coordinated 
awareness campaigns. The first campaign began in 2005, was en-
titled Clean Care is Safer Care and emphasized proper hand hy-
giene and recommendations for improved sanitation practices. As 
of 2013, 15 700 health care facilities worldwide have committed to 
the WHO guidelines for improving hand hygiene.1
The second WHO campaign, Safe Surgery Saves Lives, began 
in 2007 and aimed to reduce preventable causes of surgical com-
plications. It is estimated that 234 million surgical operations are 
performed annually around the world,2 with 3% to 17% of proce-
dures resulting in major complications and 0.4% to 0.8% in periop-
erative death.3 At least half of these adverse outcomes are thought 
to be preventable, quantified as approximately 468 000 preventable 
deaths every year.3 While the statistics urge a widespread harm 
reduction intervention, the complexities of surgical error make it 
much more difficult to address than hand hygiene. Hand hygiene 
guidelines that were put forward in the Clean Care is Safer Care 
campaign were effective because they followed the principles of 
simplicity and wide applicability. In contrast, the crucial and re-
source-sensitive challenges of surgery that are specific to any one 
ward, hospital or country can be too unique for wider application. 
Despite these challenges, the most recent WHO guidelines opti-
mistically state that these same principles will be maintained in the 
Safe Surgery Saves Lives campaign.4
the checklist
The cornerstone of the Safe Surgery Saves Lives recommenda-
tions is a 19-step surgical safety checklist that includes items for review 
prior to induction of anaesthesia and skin incision and before the pa-
tient leaves the operating room. An accompanying manual guides the 
clinician through proper use of the checklist. Checklist items include 
more universal perioperative considerations, such as patient identifi-
cation, consent and proper site of surgery, and more specific instruc-
tions, such as a prompt for two intravenous access points if more than 
500 mL of blood loss is anticipated. Communication of procedural or 
patient-specific concerns is also encouraged between members of the 
surgical team (nurse, anaesthetist and surgeon). 
A large pilot study appraised the benefit of the WHO checklist 
in 8 hospitals around the world. The rate of perioperative death from 
noncardiac surgery averaged 1.5% (n = 3733) before intervention, and 
decreased significantly to 0.8% (n = 3955) after checklist training and 
implementation.3 In the same population samples, inpatient compli-
cation rates also decreased significantly from 11.0% to 7.0%. These 
statistics align well with the estimate that half of surgical injuries are 
preventable and suggest that the checklist can accomplish a mean-
ingful reduction in these events. However, the study is plagued by 
several limitations. The researchers of the study pointed out that sur-
gical team performance may have improved during use of the check-
list as it could have heightened the teams’ awareness that they were 
being observed. They also noted that patient complications were only 
observed up until discharge, suggesting that the incidence of postsur-
gical complications could have been underestimated. 
It is important to note that the above study may lack general-
izability. While 4 of 8 hospitals belonged to low- or middle-income 
countries, only one hospital was not a large tertiary hospital in an 
urban centre. This lack of diversity raises concerns regarding the ap-
plicability of the study results to a broader range of hospital settings, 
specifically smaller or rural facilities. Pulse oximetry and prophy-
lactic antibiotics were identified in the study as requiring the com-
mitment of significant resources, and were available at the low-in-
come sites but used inconsistently prior to checklist intervention. 
The study made no comment on whether the increased use of these 
resources placed any strain on hospital supplies. Given the estimate 
that half of the world’s population lives in a rural setting,8 it was also 
misrepresentative to recruit only one rural hospital. Though recruit-
ment of hospitals from more truly diverse settings would have yield-
ed more convincing data, herein could arise the problem of global 
variability. For instance, pulse oximetry was considered to be a su-
perfluous checklist item for United Kingdom (UK) anesthetists as it 
is standard.5 Meanwhile, in developing countries, where preventable 
mortality attributed to anaesthesia can be as high as 1 in 150,9 pulse 
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clinical procedures
oximetry may frequently not be available and a serious shortage of 
trained anaesthetists may be a more pressing issue altogether.10,11
Additionally, a smaller independent study on the implementa-
tion of the checklist suggested that certain surgical subspecialties 
will need to modify the checklist. For instance, orthopaedic surgery 
will benefit from checking for prophylaxis against deep vein throm-
bosis.5 The WHO guidelines advise additions and modifications of 
the checklist to fit local practice, but do not address the inherent 
problems created by a list that becomes too lengthy. Research sug-
gests that when a list becomes too exhaustive, there is an increased 
likelihood for any checklist item to be overlooked.6 Furthermore, 
studies in aviation have pointed out that a poorly executed checklist 
can give a detrimentally false sense of security.7
While these limitations may be amenable to optimization 
through modifications of the checklist and its implementation, mat-
ters of resource limitation, as discussed previously, could pose even 
greater challenges to the checklist’s effectiveness. One UK anaesthe-
tist accurately captured this issue in a comment on the checklist: “It 
is a bit artificial sometimes. It’s trying to be everything to every nation 
and to every standard of medicine.”5
the best standards checklist
As it stands today, the current checklist and guidelines aim to 
be widely applicable by falling somewhere in between ideal and 
resource-limited surgical safety standards. This results in a dichot-
omous insufficiency. For affluent regions with developed medical 
infrastructures, the checklist may be too basic and the benefit of the 
checklist restricted.  On the other hand, for poorly-funded facilities, 
where the training or resources indicated on the checklist may not be 
available, the checklist would be unusable. We suggest that it would 
be more appropriate to maintain an updated checklist that focus-
es on the best standards of patient safety given the best reasonably 
available surgical resources. This, in combination with knowledge 
exchange and capacity-building strategies, may best pave the way to 
safer surgeries. Such a position would not neglect the right to safe 
surgery for patients in low- and middle-income countries; rather, it 
would recognize the more pressing issues of surgical availability and 
accessibility where they are limited.
where availability & accessibility are a graver concern
Though it may be beyond the scope of the WHO patient safety 
program to supply surgical resources to developing countries, it is 
imprudent of the Safe Surgery Saves Lives campaign to neglect this 
more critical challenge to safe surgical care. Given the importance 
of minimizing iatrogenesis, the developing world would be better 
served by the distribution of information on the safety of adaptations 
made for resource-limited surgery instead of financially inappropri-
ate recommendations. Surgical innovations discovered in low- and 
middle-income countries have been very cost-effective but due to 
safety concerns and lack of knowledge dissemination, these innova-
tions may take a long time before they are globally appreciated and 
adopted.12 Many such innovations like the Bogotá bag, the use of a 
mosquito net mesh for inguinal hernia repair, and manual small inci-
sion cataract surgery have drastically improved global surgical care.12 
It would also serve the additional benefit of helping to dispel the il-
lusion that essential surgeries cannot be affordable or cost-effective 
in developing countries.13 Indeed, the Safe Surgery Saves Lives cam-
paign has already endorsed the Lifebox, a more affordable yet still 
reliable pulse oximeter developed by a nonprofit organization.14
conclusion
While hand hygiene is relatively a more globally achievable mea-
sure, global surgical safety involves more procedure-specific guide-
lines and is more resource-sensitive. Simplicity and wide applicability 
helped to make the Clean Care is Safer Care campaign a success, but 
Safe Surgery Saves Lives could be made more successful with a more 
appropriate and stratified approach. We propose the following:
1. Specific guidelines should be adapted for specific areas of 
surgery. 
2. Up-to-date checklists should be maintained and based on the 
best standards of care, with fewer superfluous checklist items.
3. More parallel effort should be made to endorse and dissem-
inate safety information on surgical innovations adapted for 
resource-limited facilities. 
This approach would help to improve both the safety and the acces-
sibility of surgery on a global scale. Though preventable patient harm is 
a global issue, improving the safety of surgery requires local measures.
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abstract
Despite advances in treatment and diagnosis, malaria con-
tinues to cause a significant number of deaths, particularly in 
African children.1 Optimized diagnostic and follow-up testing 
is required for appropriate treatment and eventual eradica-
tion of malarial disease in sub-Saharan Africa. Microscopy is 
compared to rapid diagnostic testing (RDT) for use in a low-re-
source setting.  
introduction
Malaria is a curable disease caused by the infection of red 
blood cells with the parasite Plasmodium, a protozoan transmit-
ted between carriers via bites from infected Anopheles mosquitos. 
According to the World Health Organization (WHO), malaria is 
responsible for between 473 000 and 789 000 deaths worldwide 
per year.1 Most deaths occur in children living in Africa, though 
elderly individuals, immunocompromised pregnant women and 
previously unexposed travellers are also at increased risk of ex-
periencing severe disease in endemic areas.1,2  Chronic infection 
with the parasite results in partial immunity; individuals infected 
for the first time are the most vulnerable to complications of the 
disease, whereas those with chronic infections often become as-
ymptomatic carriers.1 Malarial illness typically presents with fe-
ver, chills and vomiting, making its differential diagnosis difficult 
, and may result in severe complications or death if left untreated.2 
Common complications observed in children include anemia, met-
abolic acidosis and cerebral malaria, whereas adults with severe 
disease are more likely to develop multi-organ failure.1 Childhood 
infection with malarial parasites has also been associated with in-
creased prevalence of chronic anemia and status epilepticus in Af-
rica.3,4 Thus, access to accurate and reliable diagnostic technology 
could help to reduce the burden of malaria-associated deaths and 
complications.1-4 Further, lack of accessibility and incorrect use of 
diagnostic technology has resulted in overprescription of antima-
larial drugs.2 Widespread use of artemisinin monotherapy, rather 
then the gold standard artemisinin combination therapy (ACT), 
and discontinuation of antimalarial drugs based on symptom res-
olution rather then clearance of infection have contributed to the 
development of artemisinin-resistant strains in some geographical 
areas.5 The widespread dissemination of resistant strains could 
be devastating as methods of identifying and treating drug-resis-
tant malarial strains have not yet been developed.5 Improved ac-
cessibility to accurate malaria diagnosis in sub-Saharan Africa is 
necessary for elimination of malaria as it ensures that individu-
als presenting with fever are treated appropriately, thus reducing 
overprescription and transmission to more vulnerable populations. 
Though several tests exist for the diagnosis of malaria, there 
are many challenges to implementing them in sub-Saharan Africa. 
Previous efforts to eliminate malaria in this setting have failed de-
spite the availability of diagnostic testing. Possible barriers to im-
plementation may include poor infrastructure maintenance, lack of 
trained microscopy personnel, expiration or degradation of testing 
materials caused by heat and humidity, high financial costs and 
lack of quality control measures. In order to increase accessibility 
to testing in this setting, tests need to be sensitive and specific, but 
also easy to use, able to provide results rapidly and tolerant of poor 
storage conditions.  This article will discuss the benefits and draw-
backs of two commonly used technologies: microscopy and rapid 
diagnostic testing (RDT).
microscopy
Microscopy with Giemsa staining is considered the gold stan-
dard for diagnosis of malaria.6 Several different methods of microsco-
py are currently available. Thick blood smear microscopy examines 
a larger volume of blood and is thus useful for determining whether 
the parasite is present.6 Thin blood smear microscopy is less sensitive 
because a smaller volume of blood is used, but is more effective at 
determining parasite species: as such, it gives valuable information 
about a patient’s risk for complications and the appropriate course 
of action.6
Microscopy performed in a clinical setting with skilled person-
nel is the most sensitive form of testing available for malaria diagno-
sis; detection of parasitemia can occur at concentrations of 4 to 20 
parasites per µL.6 However, this level of sensitivity is achievable only 
by experienced microscopists with adequate supplies and training.7,8 
Field studies in Africa have demonstrated that parasitemia levels as 
high as 50 to 100 parasites per µL may be required for detection of 
malaria in local laboratory settings.7,8 Several studies conducted in 
febrile patients diagnosed with malaria have found poor agreement 
between regular microscopy and research microscopy and suggest 
that antimalarial overprescription rates may approach 50% in some 
areas.9 Sensitivity and specificity of regular microscopy was also 
found to vary considerably among different facilities, suggesting that 
the efficacy of microscopy is dependent upon the expertise of the mi-
croscopist.9,10 Several studies have been conducted in an African set-
ting comparing routine microscopy to research microscopy. Results 
suggest that routine microscopy performs poorly in low-resource 
settings, with one trial finding that positive tests were confirmed by 
research microscopy only 43% of the time and the other, a study con-
ducted in Dar es Salaam, finding only a 47% specificity for routine 
microscopy.2,10 It is therefore not surprising that a survey conduct-
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ed of clinicians in Tanzania found that only 41% considered malaria 
results from their local laboratory to be reliable.11 Reasons cited for 
poor laboratory performance include lack of equipment or stain, lack 
of training and low job motivation.11 Further, in both Ghana and Ma-
lawi, it was found that treatment is frequently administered despite 
negative test results.12 Thus, though microscopy can be highly effec-
tive at detecting parasitemia and differentiating between species of 
malaria, in the absence of appropriate resources and skilled techni-
cians, it loses its diagnostic efficacy and may contribute to the over-
prescription of antimalarial drugs.
rapid diagnostic testing
Rapid diagnostic testing (RDT) is the use of immunochromo-
graphic assay with monoclonal antibodies to determine whether a 
blood sample contains protein markers specific for malaria. The test 
is simple to interpret and a result can be obtained in 5 to 20 minutes. 
Thus, use of these tests requires little training.  Also, RDT kits are 
more transportable than microscopes and require no electricity, thus 
making them easier to implement in low-resource or rural settings.10 
The same study that found low specificity for routine microscopy 
in clinics in Dar es Salaam reported the sensitivity and specificity 
of RDT to be  97% and 96.8%, respectively.10 Implementing RDT in 
this setting significantly reduced false positive test rates from 43% in 
hospitals and 62% in health centers to 6% and 7%, respectively, after 
RDT implementation.10 This observed true  positive rate was similar 
to the rates of parasitemia in febrile patients found in a cross-sec-
tional study of the region conducted at the same time.10 This suggests 
that the use of RDT could help to reduce overdiagnosis of malaria 
as well as the costs associated with overprescription of antimalarial 
drugs. A study conducted in Tanzania looked at the safety, measured 
by complication rate, of withholding antimalarial treatment based 
on RDT test results in 1000 febrile children with a mean age of 24 
months.13 At 7 day follow-up, none of the 603 children who tested 
negative for malaria had malaria-related complications, though 4 
were admitted to hospitals for other reasons, and 3 of the children 
who initially tested negative tested positive 2, 4 or 7 days after ini-
tial testing.13 Children are at highest risk for malaria-related death 
in this region, and these results suggest that RDT could be a safe and 
cost-effective way to diagnose malaria and reduce overuse of antima-
larial drugs in this population.5
It needs to be noted that there are several drawbacks to the use 
of RDTs. Firstly there are many products available on the market, 
which may use different antigens and have different sensitivities to 
parasitemia. Histidine-rich protein 2 (HRP2) has been demonstrated 
to have P falciparum sensitivity of greater than 95% in several clinical 
trials, but results may vary considerably between kits and much lower 
sensitivities have been reported for other species.14-19 Assays using P 
falciparum lactate dehydrogenase (pLDH) or an aldolase, which are 
considered pan-malarial antigens, are also common, but some studies 
have reported sensitivities as low as 61% to 76% for non-falciparum 
species detection as well as decreasing test performance at lower lev-
els of parasitemia.17-19 This means that asymptomatic carriers could 
go undiagnosed and untreated, resulting in continued propagation of 
the disease. As well, HRP2-specific assays are prone to false positives, 
as HRP-2 may take a long time to clear from the body or may remain 
elevated due to the presence of gametocytes, making this assay less 
useful for monitoring parasite clearance.20 This means clinicians may 
have to use one kit for diagnosis and a second for follow-up. Some of 
the observed poor results in trials may have been caused by product 
instability at temperatures greater then 30°C or by quality control 
issues during manufacturing.14 In order to address quality control is-
sues, the WHO has created an initiative for quality assurance of RDTs 
that outlines an appropriate product testing protocol, monitors prod-
uct quality and provides information to health care providers about 
the quality and efficacy of each product.21 This initiative has provided 
standards for specificity and sensitivity of RDTs as well as introduced 
quality control protocols to product manufacturing and testing, thus 
making RDT more robust and reliable in low-resource settings.21
conclusions
Though expert microscopy remains the most sensitive and spe-
cific test for malaria diagnosis, the limited availability of appropriate 
lab infrastructure and expert microscopists in sub-Saharan Africa re-
duces its usefulness in this setting. Inaccurate malarial diagnosis may 
cause physicians to miss other potentially deadly causes of fever and 
may contribute to the overprescription of antimalarial agents and the 
evolution of drug-resistant malaria strains. RDTs have been shown 
to be both safe and cost-effective in the diagnosis of malaria, are sim-
ple to use and interpret and require little training or maintenance of 
infrastructure. Thus, RDTs may be a preferable method of malaria 
diagnosis in low-resource and rural settings. 
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ethics & law
Public health, as today’s physicians have come to understand it, 
is a concept that extends beyond the control of infectious disease and 
harmful pollutants to encompass social welfare and advocacy.1 The 
concept that physicians and healthcare organizations have a profes-
sional duty to advocate for social, economic, and political reform as 
a method to alleviate population-wide determinants of health dates 
back to at least the 1940s, when the newly founded World Health 
Organization (WHO) defined health as “a state of complete physical, 
mental and social well-being and not merely the absence of disease 
or infirmity.”2 The WHO definition continues to exert influence de-
spite the criticisms it has drawn over decades. This definition right-
ly assumes that health is not merely a negative concept—the mere 
absence of disease symptoms—but that it must comprise something 
more. In modern medical education, this definition has been inter-
preted as a professional responsibility for physicians to look beyond 
the direct patient interaction and to become advocates and agents 
for the reform of economic inequalities, discriminatory social insti-
tutions, and cultural prejudices.3,4 In this article, the authors call for a 
debate about the merits of this public health paradigm. 
the case against it
The approach to healthcare that is implied by the World Health 
Organization’s (WHO) definition has won many adherents, yet it 
also has its share of critics. Surprisingly, some of the most powerful 
arguments that critics have been making since at least the 1970s re-
main only partially addressed by proponents of the current health-
care paradigm.
There are two fairly straightforward criticisms, which may be 
stated briefly.5 In the first case, suggesting that broader social and 
economic reform is within the scope of modern medicine may as-
cribe too much authority to physicians. Physicians are not politicians. 
A separate criticism is that such a conception of public health vastly 
expands our ordinary notion of “health” to include potentially most 
of what we would normally understand to constitute human happi-
ness. Indeed, what human goods, whether individual or social, might 
not be understood to fall within a state of physical, mental, and social 
well-being that is “complete”? Both criticisms remain weighty ob-
jections that must chasten the reformist zeal of any physicians who 
claim the authority to take leadership roles in institutional reform as 
their professional prerogative. Nevertheless, these two criticisms do 
not decisively nor necessarily defeat the social welfare idea of pub-
lic health. Nothing prevents physicians from informing themselves 
and becoming more expert in public policy matters. On the contrary, 
well-informed physicians who understand the inherent limitations of 
the perspective of their profession could be a valuable voice in public 
policy debates. As long as professionals keep in mind that health is 
distinct from broader concepts such as subjective happiness, and that 
it is only one precondition of a full human life, we will avoid confu-
sion regarding the fundamentals.
Beyond these more or less straightforward criticisms, howev-
er, there are more profound philosophical objections that challenge 
the current public health paradigm in a more radical way. Several 
decades ago, Ivan Ilich argued that by transforming pain, illness, 
and death into a set of purely technical problems, to be addressed 
over time by medical science, we have made these problems not 
more, but less manageable.5 According to Ilich, modern medicine 
has sold the public a false bill of goods: for at least a century it has 
held out the promise of an ever-increasing lifespan and of the erad-
ication of an increasing number of devastating diseases. This prom-
ise has proven to be only an illusion: the diseases we have eradicat-
ed (small pox, measles) have been replaced by new ones (cancer, 
obesity, mental illness). Yet not only have we replaced one set of 
illnesses with another; perhaps more importantly, we have also 
rendered ourselves complacent regarding the inevitability of our 
mortality. The illusory belief that with sufficient advancement in 
medical science we will one day be able to conquer pain and dis-
ease has gradually led our society into a perpetual denial of the need 
for each one of us to face the inevitability of disease, and ultimately 
death. Conversely, according to the conception of health favoured 
by Ilich himself,
[h]ealth designates a process of adaptation. It is not the re-
sult of instinct (ie, to avoid pain), but of autonomous and 
live reaction to an experienced reality. It designates the 
ability to adapt to changing environments, to growing up 
and to ageing, to healing when damaged, to suffering and 
to the peaceful expectation of death. Health embraces the 
future as well, and therefore includes anguish and the in-
ner resource to live with it.5
In addition to traditional modes of medical intervention, “wel-
fare, international relief, and development programmes are enlisted 
in this struggle” to obscure the true problem of health—the expan-
sive, social welfare idea of public health would rob us of the hu-
mane task of coming to terms with our fate as mortal beings.5
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the case for a social welfare idea of public health
Article 27 of the Universal Declaration of Human Rights, ad-
opted by the United Nations General Assembly, states that everyone 
has the right to share in scientific and medical advancements, and 
their benefits.7 The International Covenant on Economic, Social, and 
Cultural Rights includes the right to health as a basic right, and the 
definition also includes the right to the social determinants of health, 
such as housing and nutritious food, with the understanding that 
they contribute significantly to health outcomes.8 This is a key point. 
There is considerable evidence to suggest that the process of neolib-
eral economic policies and globalization has hollowed out the health 
systems of the Global South and made the poor ever poorer.2 Increas-
ing privatization and trade reforms have made access to healthcare 
difficult, and have also reshaped access to the social determinants of 
health, such as food and housing. For instance, neoliberal trade re-
forms have damaged local food security in the Global South by en-
couraging a shift to store-bought food away from local food,8 which 
in turn has not only resulted in an increase in prices, but also in the 
incidence of diabetes and obesity.8
Human rights, and especially a rights-based approach to health, 
offer an alternative to neoliberal policies8 in that they eschew 
cost-effectiveness when it comes to human life. Instead they posit 
that doctors can, and should, advocate for policies that consider the 
social determinants of health. Healthcare providers can lessen the 
impact of social inequalities, especially since the natural history of 
disease encompasses social phenomena.9 For example, tuberculosis 
disproportionately affects First Nations, partly due to cramped living 
conditions and the poor ventilation found in substandard housing 
on reserves, which has risen as a result of a history of governmental 
neglect and historical circumstances. Simply treating tuberculosis 
in this situation will not address the social determinants of the ill-
ness.9 Although Rene Dubos may have expressed doubt in the lack of 
training that physicians have in political advocacy, he also mentions 
repeatedly throughout his book Mirage of Health that one cannot for-
get that improvements in socioeconomic conditions since the 19th 
century have been the true major cause of the decline in the inci-
dence of communicable diseases in the Western world.10 The reform 
movements of the 19th and 20th centuries directly took on the poor 
living conditions that lead to such unconscionably high incidences 
of diseases, such as tuberculosis and cholera, amongst the working 
classes. One of the doctors at the forefront of the reform movement 
was none other than Rudolf Virchow, who was a pathologist and civic 
and public health reformer. Virchow is famous for having said that 
“physicians are the natural attorneys of the poor.”7
Dr Paul Farmer has perhaps been the one health scholar who 
has been able to clearly articulate the rationale for a rights-based ap-
proach to health, and its demands on physicians. He has been able to 
meld liberation theology’s demands for the rights of the poor with 
conventional human rights analysis and work, and thus refocus our 
attention on social justice and towards the fundamental moral equal-
ity of all persons.5,11,12
Dr Farmer’s writings are primarily concerned with the upstream 
social determinants of health, specifically with those factors that he 
defines as constituting a form of structural violence. Structural vio-
lence refers to social structures that stop individuals, groups, and so-
cieties from reaching their full potential.8 It is related to the concept 
of structural oppression, which more generally speaks to socioeco-
nomic conditions such as poverty and racism that lead to the viola-
tions of people’s civil, political, and economic rights. For instance, al-
though the Canada Health Act guarantees access to healthcare with 
no direct nor indirect barriers, the existence of historically under-
served populations, such as the First Nations or the lesbian-gay-bi-
sexual-transexual-queer community, give evidence to the fact that in 
practice, these groups as well as many others have been effectively 
disenfranchised of their right to health. 
Structural violence is a powerful concept in understanding the 
pathology of society’s ills. It challenges the community of medicine to 
understand that although vulnerable populations are offered formal 
rights in Canada or abroad, the actual enforcement of those rights 
is spotty at best. The concept of structural violence also posits that 
even where civil and political rights are equally exercised (freedom 
of speech, association, etc), disparities in economic rights, such as a 
right to an education, to housing, and to health, affect people on a 
more substantive level.6 It is in this vein that Dr Farmer advocates 
for approaching the diagnosis and treatment of diseases as a public 
good.5 Medical services are not just commodities to be purchased 
and delivered—indeed this is the core belief of a rights-based ap-
proach to health. 
In conclusion, the inextricable link between the natural histories 
of diseases and socioeconomic factors, such as race and poverty, de-
mand that physicians advocate and work to ameliorate those factors 
that continue to perpetuate and maintain disease. Physicians should 
certainly understand the lack of training in politics that most of them 
have, as well as be humble about their ability to significantly treat the 
socioeconomic determinants of health.
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Deadline approaching
Millennium Developmental Goals
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what are the millennium developmental goals?
In September 2000, over 150 world leaders gathered in New 
York City at the United Nations (UN) Headquarters for an event 
called the Millennium Summit. Its purpose was to discuss what the 
role of the UN would be in the 21st century. As a product of these 
discussions, 189 nations ratified the United Nations Millennium 
Declaration, which included eight broad Millennium Development 
Goals (MDGs) that lay out numerous specific quantitative targets 
for improvement of various health and economic indicators in de-
veloping nations of the world.  
With less than a year to go before the 2015 deadline on most of 
these goals, progress varies considerably. We examined how several 
global health-related goals were progressing toward their targets: 
specifically Goal 6, regarding the halting of Human Immunodefi-
ciency Virus (HIV) spread and universal access to treatment for the 
disease, as well as Goal 4, regarding the reduction of child mortality.
goal 6: combatting hiv/aids
Since the Millennium Declaration was signed, global funding 
devoted to combatting HIV has increased over tenfold, from US 
$1.6 billion in 2001 to over US $16 billion annually in 2010, resulting 
in a significant reduction in global HIV burden.9 The development 
and mass production of HIV-fighting drugs at substantially lowered 
prices compared to those seen in developed nations has reduced 
the worldwide number of deaths from HIV by 25% in just the past 6 
years.7 An especially effective strategy in combatting HIV has been 
the formation of the Medicines Patent Pool, a UN initiative which 
allows the production of generic HIV, malaria, and tuberculosis 
pharmaceuticals in high-risk countries while waiving or discount-
ing the drugs’ expensive patent fees. In 2000, the global average 
cost of HIV treatment neared US $10 000 annually; however, with 
the advent of fixed-dose combination pills (a single pill containing 
multiple HIV medications) and the creation of the Medicines Pat-
ent Pool, this annual cost has dropped to a median of US $137 per 
person,10 and under US $70 in some nations.11 This represents an 
incredible 99% reduction in price in only a decade.
Despite these breakthroughs, as of 2011 only 8 million (55%) of 
the approximately 15 million people in developing countries who 
require HIV treatment actually receive it—far from the UN’s goal of 
universal access to treatment.7 This still marks a massive improve-
ment over the past decade, where less than 400 000 people received 
treatment in 2002.10 In developing nations, access to treatment has 
been steadily increasing, to the current high of 1.5 million newly 
treated people per year. This improvement means that the number 
of people in developing nations receiving HIV treatment will hit an 
astounding 15 million by 2015—nearly double the figures from 2011, 
and very close to the UN’s overall goal.7
The annual HIV infection rate has decreased over 21% global-
ly since the creation of the MDGs, yet still more can be done. The 
greatest effects on global HIV burden can be exerted by focusing 
more attention on the highest-risk area: sub-Saharan Africa. Of the 
2.5 million people in the world that became infected with HIV in 
2011, 1.8 million (approximately 70%) were in sub-Saharan Africa, 
where the current rate of infection nears an unbelievable 1 in 20. 
The simplest, most cost effective way to curb the spread of HIV 
in this region (and globally) is by promoting education about modes 
of viral transmission and methods of safe sex, as well as distribut-
ing condoms. Research indicates that the introduction of safe-sex 
education programs such as Asia’s 100% Condom Use Programme 
has been extremely successful, more than doubling the use of con-
doms in Cambodia and preventing 6 million HIV infections over 15 
years in the handful of Asian countries that adopted the program.12 
However, currently only 30% to 35% of sub-Saharan Africans are 
educated on how HIV is transmitted, up barely 5% from a decade 
ago. Similarly, the use of condoms has increased only 5% to 10% in 
that time period, now hovering at around 40%.7 
One of several reasons for this failure to implement change in 
sub-Saharan Africa pertains to the quality of education in these na-
tions. For example, sub-Saharan African populations comprise over 
half of the world’s out-of-school children, with enrollment rates at 
approximately 77%, and over one quarter of these students drop out 
before reaching the end of primary school education. Literacy rates 
reflect these disparities, as only 65% of women and 75% of men are 
able to read and write, representing less than 5% improvement in 
the last 20 years.7 Addressing this sizeable barrier to sexual educa-
tion lies under the purview of another of the MDGs (Goal 2, univer-
sal primary education), and it may be that progress must be made 
there before sexual education can become more prevalent and an 
effective HIV-deterrent in sub-Saharan Africa.
goal 4: reduce child mortality
Another important MDG is Goal 4, reducing child mortality. 
The original target was to reduce the mortality rate of children 
under 5 by two-thirds by 2015. Not surprisingly, populations more 
likely to experience high rates of child mortality tend to be the 
poorest and most marginalized,1 highlighting the relationship be-
tween economic wellbeing and health outcomes.
About 40.3% of deaths among children under 5 years of age 
occurred in neonates, with preterm-birth complications and intra-
partum-related events as the leading causes. Precluding neonatal 
deaths, the leading causes of child mortality are pneumonia, diar-
rhea, and malaria.2
Deconstructing these causes of mortality further necessitates 
the discussion of social determinants of health. Generally, it is the 
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socioeconomically disadvantaged populations of sub-Saharan Afri-
ca and South Asia that bear the majority of child mortality burden. 
Living in remote rural areas, these populations often have limited 
access to health services and social supports that are known con-
tributors to health. Still, there is also an appreciable burden borne 
by poor urbanites. It has been reported that factors such as hygiene, 
overcrowding, and air and water quality may be even worse in ur-
ban areas, eliminating the notion of an “urban advantage”.3,4
The link between poverty and undernutrition has been well 
recognized. It has been estimated that about 45% of all child deaths 
are associated with undernutrition. Rates of stunting, wasting, and 
fetal growth restriction are especially high in sub-Saharan Africa 
and Asia, and are slow to decrease. Compounding the problem is 
increasing food prices, with global food price indices reaching peak 
levels in recent years.3
Fortunately, there has been progress. In 1990, the mortality rate 
for children worldwide was 90 deaths per 1000 live births. As of 
early 2014, this figure has dropped by 48% to 48 deaths per 1000 live 
births.1 Africa in particular has seen some of the greatest decreases 
in child mortality ever recorded. Of 20 African countries in which 
the World Bank has conducted detailed surveys of living conditions 
since 2005, 16 have recorded falling rates of child mortality. Addi-
tionally, 12 nations have had rates of reduction of 4.4% or greater, 
putting them well on their way to meeting the 2015 goal. These dra-
matic reductions in child mortality have crossed geographical and 
cultural boundaries, with countries all across the continent, Chris-
tian and Muslim, cutting child mortality rates. South Asia, with the 
second-highest child mortality rate in the world, has seen similar 
successes.5
Broad economic growth as well as public health interventions 
have been the most important strategies for combatting child mor-
tality.6 In Chad, a UNICEF (United Nations International Chil-
dren’s Emergency Fund)-sponsored immunization program has 
greatly reduced under-5 mortality. Similarly, in Cambodia, measles 
immunization increased by 71% between 2000 and 2012, and with 
support from the World Health Organization (WHO) in reaching 
communities that were missing out, Cambodia reported no measles 
cases in 2012. In India and Nigeria, increasing healthcare access 
to rural communities and women and children, respectively, have 
been effective strategies.1
Even with great progress, many organizations cite that the rate 
of improvement in many countries is still not high enough to meet 
goal 4 by the 2015 deadline. In the UN’s 2013 progress chart, it is 
reported that sub-Saharan Africa, Southern Asia, Oceania, the Cau-
casus and Central Asia still have insufficient progress to meet the 
2015 deadline despite vast improvements since 1990.7 Becoming a 
recent priority is neonatal death, which was cited earlier to com-
prise a large proportion of under-5 deaths. Troublingly, while the 
rate of child mortality has decreased rapidly since 1990, the rate of 
neonatal death has been much slower to do so and now comprises 
an even larger proportion of under-5 deaths.  
A more intensive effort is now being made to reduce neonatal 
death, as evidenced by a global decrease in neonatal mortality, but 
novel strategies must be employed as the requirements to reduce 
neonatal mortality differ from those needed to address under-5 
mortality. One cost-effective strategy that is suggested in the 2013 
UN report is that of postnatal home visits to promote healthy be-
haviours such as breastfeeding and clean cord care.8
Although not all targets will be met by the self-imposed 2015 
deadline, it is undisputable that the pursuit of the Millennium De-
velopment Goals has had a vastly positive impact on vulnerable 
populations across the globe. As we progress further into the 21st 
century, one can only hope that the current promising trends re-
garding socioeconomic progress and the promotion of global health 
will continue, and that developed nations will only heighten their 
role in helping this change endure.
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abstract
Perhaps the greatest medical advancement in history was the 
development of the vaccine. While previously helpless to stop the 
spread of deadly infectious diseases, humanity has since harnessed 
the power of vaccination and decreased the incidence of infectious 
disease across the globe. Smallpox was the first disease to be erad-
icated—the greatest of our triumphs. This success was due to the 
global coordinated effort of the Intensified Smallpox Eradication 
Program. Presently, measles is the top cause of vaccine-prevent-
able death in the world, and despite enormous vaccination efforts, 
eradication is still distant. This is due in part to the antivaccination 
movement, which was fueled by an article by Wakefield, published 
in the Lancet in 1998. The future of vaccination is an ambitious and 
unclear one—with tremendous financial support and involvement, 
the Global Vaccine Action Plan (GVAP) aims to eliminate vaccine 
preventable illness within what they call the “Decade of Vaccines”.
past: smallpox
The most illustrative example of the power of vaccination to 
alter disease prevalence around the world is undoubtedly the erad-
ication of smallpox. The earliest signs of smallpox were found in 
mummified Egyptian remains approximately 3000 years old. It 
existed throughout China and India, was established in Europe 
during the Crusades, and was spread to the Caribbean and Amer-
icas following European colonization.1
Smallpox was an exclusively human disease (there is no animal 
reservoir, nor does it exist in the environment), meaning that in or-
der to propagate, the disease had to be transferred between human 
hosts; this factor made the disease amenable to eradication.1 None-
theless, in its time, smallpox was a disease of historical significance. 
By the end of the 18th century, smallpox had killed approximately 
400 000 people each year in Europe—notably, 5 monarchs—and 
caused one-third of all blindness. During the 20th century, about 
500 million people died from smallpox worldwide, particularly as a 
result of large epidemics in Asia, Africa, and South America.2,3 
While Dr Edward Jenner is commonly considered the father 
of vaccination, his smallpox vaccine was pre-dated by the prac-
tice of variolation, in which susceptible individuals had their skin 
scratched and the scratches inoculated with material from smallpox 
lesions. Variolation resulted in mortality in about 2% of cases (low-
er than the rate of natural infection) and was practiced through-
out Asia and Africa for centuries. In 1796, Jenner began inoculating 
susceptible individuals with cowpox as a vaccine for smallpox—he 
called his inoculum varioale vaccine (from the Latin, vacca, for 
“cow”), a term which was redefined by Louis Pasteur to mean any 
protective inoculation. While these early attempts slowed the dis-
ease, they were not responsible for its eradication.2
The true potential for vaccination was fully realized with the 
Intensified Smallpox Eradication Program, initiated in 1967 after 
the success of mass vaccination in Western Europe, North Ameri-
ca, Japan, and several other developed nations. In 1964, the World 
Health Organization (WHO) recommended vaccination of 100% 
of the population, and in 1966 the WHO allocated US $2.4 million 
from their budget to carry out this recommendation. Several break-
throughs proved key to the successful eradication of the disease, 
including the development of the quality-controlled, heat-stable, 
freeze-dried vaccine, and its highly efficient partner, the bifurcated 
needle, both of which enhanced the delivery, efficiency, and cost-ef-
fectiveness of the vaccine. Specific surveillance strategies were de-
veloped to help detect and report smallpox; this was particularly 
critical for eradication in endemic areas with poor health services 
since it allowed outbreaks to be rapidly identified and isolated.1,4
In 1977, the last naturally occurring case of smallpox was found 
in Somalia. Two years later, the WHO declared worldwide eradica-
tion of smallpox on December 9, 1979. As a result of global eradica-
tion—which cost US $300 million—US $1 billion are saved annually.4
More than a lesson in history, the eradication of smallpox can 
act as proof of the power of vaccination to save both lives and mon-
ey, and its tale offers many lessons that can be applied to current 
and future diseases.
present: measles
Measles is among the top causes of death in developing nations, 
and is the top vaccine-preventable killer with a death toll around 
138 000 in 2010.5 The WHO reports that it is moving towards erad-
ication of the disease less aggressively than with the eradication of 
smallpox; in 2010, the WHO agreed on a target of 95% reduction 
in measles mortality by 2015 as the next step towards its eventual 
eradication.6 Indeed the prevalence of measles has been drastical-
ly reduced since the release of the vaccine; while previously 3 to 
4 million people in the United States were infected each year, and 
400 to 500 died, as of 2012, only 55 cases of measles were reported 
in the United States. This represents a greater than 99% reduction, 
but unfortunately is not typical of all countries. In underdeveloped 
nations, where health care is poor, vaccine coverage for measles 
was approximately 15% lower than developed nations in 2010.7-9 
Thus, successful eradication and control of disease is dependent on 
the addressing of logistical needs specific to underdeveloped areas. 
The WHO has some strategies for overcoming this lack of coverage, 
such as the incorporation of vaccine programmes focused on eradi-
cation into national health programmes.6
A major setback in the battle against measles has been the re-
cent antimeasles vaccine movement in developed countries. This 
controversy began initially in 1998 with the publication in the Lancet 
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of research that demonstrated a link between the measles, mumps, 
and rubella (MMR) vaccine and gastrointestinal disease and devel-
opmental regression (notably autism spectrum disorder) in chil-
dren.10 This article sparked uproar in the medical community, with 
numerous editorials appearing in the Lancet and several indepen-
dent investigations looking at the methods and circumstances sur-
rounding the research. The article was partially retracted in 2004 
and completely retracted in 2010 by the Lancet, due to proof and ad-
missions by some of the authors that the research was fraudulent.11 
An investigative journalist, Brian Deer, discovered undeclared con-
flicts of interest, manipulation and fabrication of evidence, and the 
violation of several ethical codes on the part of the primary author, 
Andrew Wakefield, resulting in the loss of his license to practice 
medicine in the United Kingdom.12-14 Despite the retraction of the 
article and the exposure of Wakefield’s research as fraudulent, there 
were immediate population consequences of underimmunization. 
For example, between December 1999 and July 2000, an outbreak 
of measles occurred in Ireland, resulting in 111 hospitalized children 
and 3 deaths; this outbreak was the result of suboptimal (< 70%) vac-
cination following the Wakefield article.15
Even now, the antivaccination movement challenges the MMR 
and other vaccines, threatening eradication efforts being undertaken 
worldwide. One reason the movement is still alive is due to the work 
of semicelebrity figureheads, such as Jenny McCarthy, an American 
model, and Jim Carrey, a Canadian actor, who garner media attention 
for the cause through outlets such as Oprah, Larry King Live, and 
Good Morning America.16 In fact, Jenny McCarthy has stimulated 
the American antivaccination movement to such an extent that an 
online counter was made at jennymccarthybodycount.com to record 
approximately how many preventable illnesses and deaths resulted 
from her endorsement of the movement.17 Aside from following the 
advice of these figureheads, parents give many reasons for refusing 
vaccination, including religious objection, complementary or alter-
native medicine preference, doubts about vaccine safety, and person-
al ignorance.18 Ultimately, to win the battle against measles and other 
vaccine preventable illnesses both at home and abroad, public trust 
in vaccination must be re-established.
future: global vaccine action plan (gvap)
In May 2012, the World Health Assembly developed a frame-
work meant to provide “immunization to all people, regardless of 
where they are born, who they are, or where they live.” This was 
the Global Vaccine Action Plan (GVAP), a vaccination strategy for 
global health that receives major contributions from the WHO, 
the US National Institute of Allergies and Infectious Diseases, the 
United Nations Children’s Fund (UNICEF), and the GAVI Alliance 
(formerly the Global Alliance for Vaccines and Immunization), 
a branch of the Bill & Melinda Gates Foundation. This plan sets a 
deadline of 2020—the end of the Decade of Vaccines.19 The goal is 
to eliminate vaccine preventable illness within the decade.20 The 
GVAP embraces 6 strategic objectives: 
1. All countries commit to immunization as a priority: this 
requires countries to pass legislation providing a budget for 
immunization, monitoring, and reporting, and to set specific 
morbidity and mortality reduction targets. It also asks that 
countries continue to act as immunization advocates for their 
own populations, and for other countries.
2. Individuals and communities understand the value of vaccines 
and demand immunization as both their right and respon-
sibility: this asks countries to promote vaccination through 
education, and to create incentives for households and health 
workers to receive immunizations. It emphasizes particularly 
the need for professionals trained to address vaccine hesitancy 
and respond to reports of adverse events in order to maintain 
public trust of vaccines.
3. The benefits of immunization are equitably extended to all 
people: this asks countries to reach out to underserved or 
marginalized groups, and to develop immunization strategies 
specifically tailored to the needs of each particular group. It 
encourages the use of existing health care systems and profes-
sionals to track individual immunization histories, and aims to 
develop new approaches to engage urban and peri-urban areas.
4. Strong immunization systems are an integral part of a 
well-functioning health system: this asks countries to focus 
on eradication, elimination and integration of immunization 
into existing national health programs. It also encourages the 
improvement of monitoring and surveillance systems through 
better data collection and analysis, and of the availability and 
reliability of vaccines through increased cold storage capacity.
5. Immunization programmes have sustainable access to predict-
able funding, quality supply, and innovative technologies: this 
seeks to increase funding toward immunization, especially in 
low- and middle-income countries, and to increase the afford-
ability of vaccination. 
6. Country, regional, and global research and development inno-
vations maximize the benefits of immunization: this encourag-
es the development of vaccine innovations such as nonsyringe 
delivery, thermostable vaccines, and more affordable manufac-
turing facilities, and also research into fundamental knowledge 
about vaccine-preventable illnesses, including epidemiology, 
behavior in the body, and response to vaccination efforts.21
The GVAP is the largest concerted effort to immunize the 
world’s population against vaccine preventable diseases. Though 
these efforts are well underway, whether or not the goal of the De-
cade of Vaccines will be reached remains unclear. With 6 years re-
maining, anything could happen. Learning from our previous suc-
cesses with smallpox, vaccine preventable diseases can surely be 
made obsolete. Though it may require dedication, innovation, and 
education in equal measure, the demise of vaccine preventable dis-
eases is on the horizon. 
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The historical changes of medical tourism
Hao Li (Meds 2016), Wendy Cui (Meds 2016)
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abstract
This article explores how international medical tourism, 
the acquisition of medical services in another country for vari-
ous reasons, has changed from ancient times, to Renaissance and 
post-Renaissance Europe, and to the present. It examines the so-
ciocultural, medical, and environmental factors driving medical 
tourism, as well as how medical tourism has in turn influenced 
humanity. We take a look at the current trends in medical tour-
ism with examples of the most popular destination countries. Fi-
nally, we will address potential future developments in medical 
tourism and the associated issues.
introduction
The term “medical tourism” conjures images of patients flying 
across the world to acquire a tummy tuck or heart transplant, pro-
cedures theoretically available in their own country, yet inaccessible 
due to long wait times or unbearable costs. However, medical tour-
ism has occurred in a much broader way, to different groups of peo-
ple for a variety of reasons. In fact, for the vast majority of human his-
tory, the desire to travel for the sake of health care was driven by the 
simple fact that the health service sought after did not exist at home.
medical tourism in the ancient times
Before the advent of complex technology in medicine, much of 
medical tourism consisted of mineral thermal springs and baths.1 
As historian George Weisz states, “True mineral waters were very 
much connected with place and were frequently thought to lose 
their therapeutic powers if they were moved to another location.”2 
Perhaps during no time in history was this statement more true than 
the ancient times when many baths were considered sacred. When 
the Greek empire was at the height of its power, tourists from across 
the world flocked to its healing temples.1 These included the Ascle-
pia Temples, constructed in honour of the god of medicine Asclepius, 
as well as the Sanctuary of Zeus in Olympia and the Temple of Del-
phi. Some of these temples also contained gymnasiums and places 
of prayer. Aside from commercial purposes and the demonstration 
of Greece as a superpower, such sacred healing centers undoubtedly 
promoted the popularity of the deities that they represented.
medical tourism from the renaissance to the  
19th century
The use of mineral waters, often as a component of high-alti-
tude “climatic resorts”, as a mainstay of healing and prophylaxis re-
mained popular well into the 19th century, although its association 
with religion lessened. Hydrotherapy was thought to be beneficial 
in a wide range of ailments such as pimples, gonorrhea, rheumatic 
diseases, and nervous conditions.3
In 1326, iron-rich hot springs were discovered near Ville d’Eaux 
(Town of Waters), France, making the little village famous. It was 
here that the word spa, derived from the Roman phrase salude per 
aqua (“health through waters”), was first used. The spa of Ville 
d’Eaux would later serve as host to historical giants such as Peter the 
Great and Victor Hugo.3
In the 1720s, the English city of Bath was one of the richest 
and most technologically advanced, being the first city in England 
to receive a covered sewage system. This dramatically advanced its 
spa tourism industry, and the economic benefits to the city were 
enormous. These included paved roads, streetlights, hotels, and 
beautified restaurants.1
With the widespread popularity of spas, it is not surprising that 
the financial stakes attached to them became increasingly high, with 
competition between spas. Many spas added other services, such as 
walks, music, dance, theatre, socializing, and gambling to their reper-
toire in order to attract customers. As technology became more ad-
vanced, various methods of delivering water healing were offered in 
addition to bathing, including vaporization, showering, and more. In 
France, an entire academic discipline on “medicalized thermalism” 
was established to promote the spa industry by adorning it with a 
“scientific” appearance. Funded directly by the spa industry, a large 
body of literature was produced on the basic chemistry of spa healing 
and the potential benefits it exerts on human health. Such research 
proved to be so convincing that following World War II, French spas 
obtained reimbursement from the social insurance system. Naturally, 
as spas became more touristic and commercial, suspicions concern-
ing whether they were truly dedicated to the promotion of health be-
gan to arise in the medical community.2
Furthermore, as advances in medical sciences during the 20th 
century produced more effective treatments, interest in spa healing 
declined. Previous basic science research on spas was discarded as 
academic attention turned more towards clinical trials. This signalled 
the end of the spa industry, an industry that existed since the dawn of 
mankind, as a provider of medical therapy. Many spas consequently 
left the medical business in search of other opportunities. Some be-
gan to advertise themselves as alternative therapy (which needs not 
to be shown as medically effective). Others moved into the wellness 
business, complementing mineral waters with other modalities such 
as perfumed baths, facials, massage, and physiotherapy.2
medical tourism in the 20th century
Until the late 20th century, the notion of medical tourism re-
mained within the realm of patients migrating to other countries in 
pursuit of health care not available domestically. Hence, for a lengthy 
time the United States maintained its status as a popular destination, 
due to its rapid technological advances in medical care.4 Some ex-
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ceptions to this rule existed, such as the revived interest in yoga and 
Ayurvedic medicine in India with the onset of the flower child move-
ment in the United States and the United Kingdom.1
In the 1980s and 1990s, Cuba initiated programs for foreign-
ers seeking eye, heart, and cosmetic procedures.1 These programs 
were cheaper and involved shorter wait times than the equivalent 
in the foreigners’ own countries. Other Caribbean countries, such 
as Jamaica, Barbados, and Puerto Rico, followed suit.4 Each country 
established its own niche in the medical field in order to minimize 
competition. Jamaica specialized in plastic surgery, Barbados infer-
tility, and Puerto Rico cardiovascular surgery, orthopedic surgery, 
neurology, and oncology. These programs were largely geared to-
wards patients from North America and Europe.
The year of 1997 marked the beginning of the Asian econom-
ic crisis.6 Among its many coping mechanisms, Thailand invested 
heavily in a medical tourism industry for foreigners hoping to ob-
tain affordable access to plastic surgery. It also offered sex-change 
operations with looser presurgical psychological requirements than 
those in Western countries.7 Furthermore, it established touristic 
medical centers, such as the Bumrungrad International Hospital, 
featuring interpreters and an airline ticket counter.
During this period of time, many other Asian and Latin coun-
tries founded their own touristic medical programs in the hope of 
attracting foreigners from Western countries desiring to circum-
vent lengthy wait times, formidable costs, and convoluted legal re-
strictions. Westerners, especially those seeking reproductive health 
treatments, can also use these oversea opportunities to maintain 
their social privacy. Initially such options were only available to 
wealthy Westerners able to afford the additional costs of travel 
and luxurious accommodations, but as the trend progressed, mid-
dle-class citizens were also able to take advantage of these pro-
grams.8 Medical tourism as we know it was now truly underway, 
and as expected, it carried with it both benefits and drawbacks.
Proponents argue that medical tourism, aside from improv-
ing availability of health care, also promotes patient choice, fosters 
global competition, places pressure on expensive health care facil-
ities to lower prices, and drives social and economic development.8 
The last point can be clearly seen in Cuba, where medical tourism 
is a governmental program and revenues generated used to fund its 
own public health care system.4
Critics attack medical tourism’s role in furthering the divide be-
tween social classes, with the wealthy possessing more opportunities 
and higher-quality opportunities than the less well off.9 This applies 
not only to tourists, but also to residents of the destination countries 
themselves. Many concerns have been raised on whether destination 
countries are diverting medical resources from serving their own 
population to the tourism industry.4,7,10 This is especially a problem 
in countries where medical tourism is a private business.
As well, there are always concerns regarding the quality of care 
received in the destination countries.9 Furthermore, legislation and 
ethical policies differ internationally. Consequently, patients travel-
ling to international clinics may not be fully informed of the risks and 
benefits of their treatments, and may find it difficult to obtain legal 
redress if harm results.11 To address issues of quality, the Joint Com-
mission International (JCI), an accreditation body for international 
medical institutions, was established in 1997.6,12,14 However, this has 
the potential of furthering inequalities in the health care systems in 
destination countries, where the higher-income medical tourism phy-
sicians would be able to provide higher-quality care than those serving 
the local population. As well, tackling the problem of quality may not 
solve the disadvantage concerning continuity of care.9 Some patients 
return to their home countries without any documentation regarding 
the care they received abroad, making it difficult for their physicians to 
provide appropriate care in the case of complications. As an example, 
Canadian data from 1998 to 2005 revealed that 22 Canadians received 
transplants internationally. One third of these patients had no records 
upon returning, and complications included 52% with opportunistic 
infections, 38% with pyelonephritis (including multidrug-resistant 
Escherichia coli), and 27% with systemic sepsis. Compared with Ca-
nadians who received transplants at home, inferior graft survival at 3 
years was shown for patients with international transplants (98% and 
86% survival for biologically-related and emotionally-related donors in 
Canada, respectively, versus 62% for international transplants).15
current and future trends in medical tourism
Currently, 28 countries across North America, South Ameri-
ca, Asia, and Europe market their medical services internationally. 
More than 375 hospitals in 47 countries in facilities across Europe, 
the Middle East, Asia, and South America have been accredited by 
the JCI, and there are 12 million medical tourists globally. Although 
the United States is still the most common destination for Canadian 
medical tourists, there are a small number of Canadians traveling 
into developing nations for health care. Medical tourism brokerages 
exist in Canada, with at least 15 companies acting as middlemen in 
organizing hospitals, physicians, flights, and hotel reservations for 
Canadians seeking to receive health care abroad. However, these 
agencies are not required to verify credentials or licensing of facil-
ities or physicians.12
In 2006, the American Medical Association issued a new set of 
guidelines listing certain factors that patients should carefully con-
sider when entertaining the idea of medical tourism.16 This was also 
the year when the American insurance company Blue Ridge Paper 
Products, Inc introduced a medical tourism incentive into its em-
ployee benefit plan.7 Since then, many insurance plans and brokerage 
companies have been founded to capitalize on this increasingly pop-
ular and lower-cost health care option. Unfortunately, the paperwork 
can be extremely complicated, deterring some patients from consult-
ing these companies.17 Certain companies link family physicians to 
specialists in foreign countries as a way of maximizing continuity of 
care.9 However, family physicians in the Western world should not 
automatically assume that this service has been provided, and should 
take medical tourism into account when working with any patient.
The 21st century is expected to see an expansion in medical 
tourism as the demand for health care in Western countries sur-
passes the capacity that these countries are able to provide.17 Both 
advantages and drawbacks can stem from this rapidly growing phe-
nomenon, and as health care providers it is important to be able to 
counsel and manage patients who have pursued or who are consid-
ering to pursue this seemingly attractive option so that hopefully, 
the advantages can outweigh the drawbacks.
history of medicine
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background of tsunami
On the morning of December 26, 2004, an earthquake shook 
the west coast of Sumatra, causing a tsunami that inundated coastal 
communities with waves up to 30 meters high. Indonesia was the 
hardest-hit country, followed by Sri Lanka, India and Thailand. It 
was one of the deadliest natural disasters in recorded history; with 
a magnitude of 9.1, the earthquake was the third largest ever record-
ed on a seismograph. The earthquake caused the entire planet to 
vibrate as much as one centimetre and triggered other earthquakes 
as far away as Alaska.1
The tsunami killed over 275 000 people in 14 countries, left tens 
of thousands of people injured and rendered over 10 million people 
homeless and displaced. Measured in casualties, this was the single 
deadliest tsunami in recorded history.2 Children accounted for more 
than a third of those killed because “they weren’t strong enough to 
hold on to fixtures or trees to resist the surging tidal waves”3 and up 
to 4 times more women than men perished in some regions because 
they were waiting on beaches for fishermen to return.4 In addition, 
up to 9000 foreign tourists staying in seaside resorts during the holi-
day travel season were among the dead or missing.5
damage of tsunami to health care services
At a time where thousands of patients desperately needed med-
ical attention, many of the health care sectors in the affected coun-
tries were too badly crippled to adequately meet the demand. For 
example, the tsunami destroyed 53 of the 244 health clinics in Indo-
nesia, the country closest to the epicenter. In a country already low in 
numbers of doctors and nurses, it was estimated that as many as 691 
health personnel were either confirmed dead or missing.6 Also dis-
rupted were telephone lines, transportation, clean water supply and 
electricity,6 constituting a major blow to the health care system. In 
the Maldives, where 80% of the land is less than one meter above sea 
level,7 many clinics and hospitals were flooded and lost their medical 
records and equipment.8 Moreover, the island health care system de-
pended heavily on expatriate physicians and nurses, many of whom 
left to go back to their native countries to be with family.8 In Sri Lan-
ka, many of the patients who required orthopedic surgery had to be 
transferred to the inland capital of Colombo not only because the 
seaside hospitals were in poor condition that made large procedures 
risky to perform, but also because hospitals ran out of equipment.9 
relief efforts
a. local (internal) cooperation
One of the efforts that received most praise was the coordina-
tion of relief that occurred within each of the affected nations.6 For 
example, one of the more complex challenges that arose immedi-
ately after the storm was the handling of the large number of dead 
bodies. In Indonesia alone, reports indicated that there were over 
100 000 dead bodies spread over the coastal sea line, which rapidly 
overwhelmed mortuary space.6 Efforts were further complicated 
in some cases by “pressures from the media and families of tour-
ists who arrived seeking some type of closure on their relatives.”10 
Consequently, teams of health care personnel, police, military, relief 
workers and volunteers worked quickly and closely to dig out and 
handle large numbers of dead bodies in makeshift graves.8 
Moreover, in response to the initial wave of patients, some coun-
tries were able to manage the influx by transferring them to hospitals 
in unaffected regions. For example, hospitals in the Maldives were 
able to coordinate and provide patient evacuations through a fer-
ry and air charter system.10 Thailand also had pre-existing disaster 
management plans and was able to quickly provide emergency food, 
water and medical supplies to the worst-affected areas.11
While experiences of individuals left homeless by the storm var-
ied between and within areas, reports indicate that in Sri Lanka, for 
example, friends and families were largely receptive to those affect-
ed, while schools and other public buildings in the Maldives were 
opened to accommodate large numbers of people left homeless.8
B. foreign (external) cooperation between governmental 
groups, non-governmental organizations and  
military forces
The scale of the tsunami was matched by an outpouring of ma-
terial assistance. In total, US $14 billion dollars in aid was pledged.2 
Monetary aid aside, much of the relief was due to the rapid arrival of 
external emergency medical assistance. In total, the humanitarian 
relief effort brought together over 130 governmental and non-gov-
ernmental (NGO) organizations from all over the world within the 
first 2 weeks that helped to deploy emergency health care staff.10 
One of the greatest fears of the relief efforts was the possibil-
ity of epidemics due to the high population density and tropical 
climate of the affected areas.2 Fortunately, these problems were 
minimized due to the quick provision of fresh drinking water and 
sanitation facilities. The drinking water response was described as 
“timely, effective and comprehensive” and involved the combined 
efforts of United Nations agencies, NGOs, defense forces, private 
companies and individual volunteers.12
Military efforts also provided indispensable relief. In Indonesia, 
foreign militaries worked alongside national militaries and civilian 
relief teams to reach people in outlying areas that had been cut off.8 
In the Maldives, the military provided supplies and constructed tem-
porary shelters.8 In many cases, there was cooperation between re-
lief units of foreign militaries and other international organizations 
to provide initial aid and assist in reconstruction efforts.13
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c. canada’s role in relief efforts
Canadian International Development Agency 
The Canadian International Development Agency (CIDA) was 
founded in 1968 to facilitate aid to developing countries.14 In 2004 
it played a key role in coordinating and administering the financial 
aid from the Canadian government and Canadian public in areas 
affected by the tsunami: $425 million of support was given by the 
Canadian Government and $230 million was raised by the Canadi-
an public.15 CIDA also coordinated humanitarian efforts through 
working with Foreign Affairs Canada, Canadian Public Health 
Agency, United Nations, the Red Cross, Oxfam and other major aid 
agencies.15 In 2013, CIDA merged with the Department of Foreign 
and International Affairs to become the Department of Foreign Af-
fairs, Trade and Development (DFATD).14
The Canadian Red Cross
The Canadian Red Cross is a charity organization that engag-
es in humanitarian projects and disaster response worldwide. Its 
workers provided aid to Indonesia, Sri Lanka, India and the Mal-
dives using different types of emergency response units:16,17
•	 Basic Health Care Unit  
•	 Responsible for outpatient clinic services, maternal-child 
health and uncomplicated deliveries and immunization 
and nutritional surveillance
•	 Involves local health care workers, expatriate doctors 
and nurses and interpreters
•	 Referral Hospital    
•	 Functions as a first-level field hospital and can provide 
care for up to 250 000 people
•	 Provides specialist services such as traumatology, obstet-
rics and pediatrics
•	 Rapid Deployment Hospital
•	 Can be established within 48 hours 
•	 Focuses on triage, first aid, limited medical or surgical 
care and medical transport
Other emergency response units used by the Red Cross are in-
volved in logistics, communications, water provision and sanitation 
efforts.17
It should be noted that the Canadian Red Cross in Sri Lanka 
also made an effort to provide psychosocial support for traumatized 
communities.18 Following the disaster, the Canadian Red Cross 
based in Sri Lanka launched training for 49 community health 
workers in psychosocial assistance.18 Their aim was to lessen the 
impact or onset of depression, insomnia and alcohol abuse and to 
prevent suicide.18
Disaster Assistance Response Team
The disaster assistance response team (DART) is made up of 
200 Canadian Forces personnel. The purpose of DART is to provide 
emergency relief until international aid agencies are able to provide 
long-term support.19,20 The DART medical platoon treats minor in-
juries, leads preventative medicine initiatives and provides limit-
ed obstetrics; meanwhile, the engineering troop repairs roads and 
electrical systems, constructs temporary housing and operates wa-
ter supply systems.19 The remaining members of DART assist in wa-
ter sanitation, communication and security efforts.19 On January 2, 
2005 Prime Minister Paul Martin announced that DART would be 
deployed to Sri Lanka.19,20 During their mission in Sri Lanka, DART 
was able to treat more than 7620 people and produce approximate-
ly 3.5 million litres of drinking water.19
challenges related to cooperative relief efforts
Because the 2004 Indian Ocean tsunami was such a large-scale 
disaster that drew such substantial numbers of relief agencies, the 
coordination of humanitarian operations posed many challenges.10 
Many local ministries of health lacked suitable staff to coordinate 
the arrival and work of so many people, equipment and donations.10 
Separately, some of the foreign aid groups were also reluctant to 
“coordinate their approaches among themselves or with local staff” 
and were also “not familiar with the cultures involved, did not speak 
the languages of the people […] and were insensitive to the ways in 
which people in different societies respond to crisis.”8,10 Agencies 
may have also been competing for funds and visibility which also 
limited their eagerness to coordinate.10
There were other cases where lack of communication and co-
ordination contributed to resources being either duplicated or di-
rectly wasted. In one case, relief workers were sent to areas where 
help was not needed: “one wealthy foreign nation dispatched a 
team of 10 professionals to Thailand, but they were told there was 
nothing for them to do.”11 There were also reports of inappropriate 
drugs donated, including drugs that were not relevant to the emer-
gency situation or drugs that were already expired. In fact, approx-
imately 150 metric tons of unusable medications were destroyed in 
Colombo alone, the capital city of Sri Lanka.22
conclusion
The 2004 tsunami resulted in an immeasurable loss that chal-
lenged the health care systems in Indonesia, Sri Lanka, India and 
Thailand and pushed the international community to provide re-
lief. Local and foreign health care workers came together to adjust 
to the high volume of injuries and displaced individuals. Sanitation 
and preventive medicine were critical in preventing epidemics and 
further loss of life. 
Through reflecting on the events of the 2004 tsunami one can 
distill valuable insights. Following a crisis, coordination is para-
mount to ensure resources are used to their fullest potential. Fur-
thermore, nonmedical professionals such as administrators, media 
personnel, engineers, translators, military troops and grief counsel-
lors each have a significant role to play in relief efforts. Continu-
ous teamwork in the aftermath of the 2004 tsunami smoothened 
the transition of affected countries from emergency measures into 
long-term recovery efforts. 
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background
Malnutrition is one of the most serious problems facing the 
world today. The World Health Organization (WHO) estimates that 
a third of all children deaths can be attributed to malnutrition. The 
primary cause of malnutrition for the majority of the world’s popu-
lation is undernourishment: around 2 billion people are estimated to 
be malnourished globally.1
Malnutrition impairs the body’s ability to perform a number of 
functions, including mounting immune responses to pathological 
insults as well as recovering from those insults. This is particularly 
evident in acutely malnourished children, whose inability to respond 
to pathogens is largely responsible for the high case fatality rate of 
many childhood diseases in developing countries. Additionally, mal-
nutrition leads to failure to grow and thrive, developmental delays 
and illness, among other adverse effects on the body.
For many intergovernmental and nonprofit organizations, re-
sponding to malnutrition can be a difficult challenge. Providing a 
compact, affordable and nutritious supplement that is resistant to 
bacterial contamination is ideal, but often proves to be difficult in 
famine-stricken rural regions. In recent years, the development of 
ready-to-use therapeutic foods (RUTFs) has been hailed as a mile-
stone in the fight against malnutrition. RUTFs are targeted primari-
ly at acutely malnourished children in the age-range 6 to 59 months 
with a sufficient appetite, but who do not suffer severe medical com-
plications.2 RUTFs are a significant source of caloric intake and mi-
cronutrients. They are aimed at restoring a healthy weight to mal-
nourished children and decreasing the incidence of wasting and 
severe wasting. 
content
RUTFs are energy-dense, micronutrient-rich, homogeneous lip-
id pastes. Their contents vary somewhat across geographical regions 
depending on the availability of raw materials and industrial capa-
bility. However, they are often based on the F-100 formula (the stan-
dard therapeutic food deployed for severe malnourishment) with the 
addition of peanut butter. Standard RUTFs consist of peanut butter, 
milk powder, oil, sugar, vitamins and minerals.3 The main minerals 
supplemented are iron, zinc, magnesium, copper, potassium, seleni-
um and iodine. Other micronutrients include, among others, B vita-
mins such as folate and niacin.4
In terms of caloric content, most RUTFs contain between 520 and 
550 kcal/100 g. Of that, 45% to 60% is provided in the form of lipids; an-
other 10% to 12% is provided in the form of proteins.2 Administration 
to malnourished children is based on their weight and caloric needs.
Due to their low water content—2.5% at most—RUTFs do not 
provide a favorable environment for bacterial growth and have a shelf 
life of approximately two years. Additionally, they do not require 
cooking and have an acceptable taste to children. All these properties 
facilitate their use in remote and rural regions.
administration
An important advantage of RUTFs is their suitability for use by 
community members and nonmedically trained staff. Oftentimes, 
they are used in remote locations beyond the reach of the health-
care systems of famine-stricken countries. To that end, research on 
RUTFs has focused on their effectiveness in community-based and 
home-based administration settings. The target population of these 
interventions are acutely malnourished children. Of particular con-
cern in this segment are children with acute or chronic diseases. 
Malnourishment’s negative impact on the immune system adds to 
mortality and morbidity associated with those diseases.
Community-based administration has been studied in a num-
ber of countries, with several positive results reported. For instance, 
research on the use of RUTFs in Malawi during the 2006 famine 
showed promising results. In one study of around 800 malnourished 
children in remote regions, 94% recovered healthy weight after only 
8 weeks of RUTF supplementation, with a mean body weight gain 
of 2.7 g/kg/d.5 The study demonstrated that RUTF supplementation 
can be successfully administered by community centres outside the 
formal healthcare framework.
Research on RUTF home administration without the need for med-
ically trained personnel has yielded acceptable results as well. Linneman 
et al tested 3 models: medical professionals administering the treatment; 
community health aides administering the treatment to patients re-
ferred by medical professionals; and community health aides adminis-
tering the treatment without the involvement of medical professionals. 
Their results showed that level of training was not correlated with better 
outcomes and similar results were obtained from the 3 models.6
Additionally, home-based therapy with RUTF has shown superi-
ority to standard therapy in similar settings. The standard treatment 
employed to help severely malnourished children is based on World 
Health Organization (WHO) guidelines, and is usually administered 
in two phases: the first phase involves modest-protein, modest-ener-
gy milk-based liquid food and antibiotics, and the second phase uses 
high-protein, high-energy milk-based liquid food. In a study compar-
ing this standard therapy to locally produced RUTF therapy in a pop-
ulation of 1200 severely malnourished children in Malawi, Ciliberto 
et al showed that the RUTF group had a greater recovery rate and 
lower incidence of fever, cough and diarrhea.7
Similarly, in a study of children at risk of malnutrition, but who 
are not yet malnourished, RUTF showed superiority to standard sup-
plementary fortified cereal/legume-blended food. Patel et al com-
pared the effectiveness of the standard micronutrient-fortified corn/
soy-blend to RUFT in Malawi and found the latter to be 3 times as 
effective as the standard corn/soy-blend.8 Short-term preventive use 
of RUTF in nonmalnourished children was also found to be effective 
in the Niger in reducing the incidence of wasting and severe wast-
ing.9 Children infected with HIV also benefited from RUTF relative 
to those who used traditional foods.3
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challenges
local production, cost and use
While the effectiveness of RUTF in reducing malnutrition has 
been shown in some settings, local production of RUTF remains a 
particular challenge. In addition to ingredient availability, the pro-
duction of RUTF requires—at a minimum—a room free of pests and 
a mechanical mixer. Adequate monitoring and quality control is 
needed to prevent contamination and ensure safe storage and pack-
aging. RUTF generally contains little water content, making bacterial 
contamination difficult, but not impossible. Additionally, due to the 
peanut content, aflatoxins produced by Aspergillus are of particular 
concern.4 Salmonella contamination has also been reported.10
The cost of RUTF is yet another obstacle. According to the 
United Nations Children’s Fund (UNICEF), the price of RUTF has 
been steadily decreasing for the past decade,11 but it is still relatively 
high. Data from 2013 shows the cost of one RUTF carton containing 
150 sachets weighing 92 g each is around US$55. Locally produced 
RUTF has generally the same price point as RUTF produced in the 
United States or France, with production costs of around US$2.6/
kg. This makes it beyond the reach of many families impacted by 
malnutrition.4
Finally, Latham et al argue that RUTF could have significant ad-
verse effects on the health of children targeted with this therapy.10 
For instance, RUTFs contain little water but the need for children 
to consume water increases with the consumption of RUTFs. This 
in turn increases the chances that children may acquire waterborne 
illnesses common in famine-prone regions.  
need for future research
Despite the positive results from several trials, some researchers 
remain skeptical about the use of RUTF, especially for home-based 
malnutrition therapy. Schoonees12 and Latham4 argue that unbiased 
evidence is lacking and, as of last year, research is insufficient to pos-
itively establish the superiority of RUTF to standard therapy. Gera13 
argues that almost all the evidence associated with the use of RUTF 
comes from sub-Saharan Africa, making generalizations to other 
geographic locations difficult. 
conclusion
Ready-to-use therapeutic foods are relatively affordable and nu-
tritious supplements with a reasonable production potential. While 
their home-use remains controversial in some settings, RUTFs have 
been shown to be effective in a variety of circumstances. More re-
search is needed to verify these findings and study the use of RUTF 
in more diverse situations and purposes, including their preventative 
use in children prone to malnutrition.
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profiles
Dr Bhayana is a family physician in London who also works 
with the London InterCommunity Health Center (LIHC) and the 
Newcomer Health Project, a Schulich initiative. She graduated 
from the Schulich School of Medicine and Dentistry in 1985, after 
which she worked in Toronto for 5 years. She is fluent in English, 
Hindi and Punjabi, and utilizes all 3 in her community work with 
recent immigrants and refugees. We met with Dr Bhayana over the 
phone to hear her thoughts on global health, to understand her in-
volvement with multicultural initiatives and to gather advice for 
medical students interested in global health.
UWOMJ: What does global health mean to you? 
Bhooma Bhayana: Global health is such a broad topic with 
so many academic definitions. To me, global health means that 
health is beyond what we do within the confines of our clinical en-
counters. Global health encompasses principles of environmental 
health, sustainability, equity and marginalization. When we talk of 
globalization, a familiar theme is that in the process of globalizing, 
we’ve ignored social justice and equity in health. 
Tell us about your work in Toronto and how that sparked your 
interest in global health. 
In Toronto, I worked with an innovative project called the Im-
migrant Women’s Health Project based out of the Doctor’s Hospi-
tal. We parked a mobile home in front of clothing factories and per-
formed cancer screening for women working in the factories. It was 
that initiative that made me realize that “international” issues were 
the same issues present in our own backyard. From there, I decided 
to really focus on immigrant and refugee health. I came to London 
in 1989 and have been practicing here since, in a family practice as 
well as with the LIHC and now with the Newcomer Health Project. 
Tell us more about the Newcomer Health Project.
From my work with the LIHC, I had seen a number of refugees 
and immigrants over the years arrive in London. When I started my 
own practice l really missed the work, so I spoke to the executive 
director of the Cross Cultural Learner’s Center (CCLC) at the time. 
She had identified a real need: when refugees arrived, they could 
only use walk-in clinics for medical problems, which addressed im-
mediate concerns but not chronic illnesses that needed follow-up 
care. We were inspired by Kevin Pottie, a physician in Ottawa and 
champion for refugee health, who had written in the Canadian Fam-
ily Physician about a program in which medical students took the 
initial history at the clinic he worked at. It was a win-win situation: 
students would learn about cultural competency and the challenges 
faced by refugees, and refugees would have an opportunity to share 
their stories, give an in-depth history and begin to look after their 
health. We decided to duplicate that here and began a clinic on an 
ad-hoc basis. Now, we’re at the point where we’re working with 
pediatricians and internal medicine specialists to provide specialty 
clinics. It is an ever-evolving process.
What are some challenges facing refugees in Canada today? 
There were some very large cuts that were announced to ref-
ugee health. Previously, all refugees were covered by the Interim 
Federal Health Program (IFHP) and government-assisted refugees 
were covered by IFH as well as the Ontario Health Insurance Plan 
(OHIP). The IFHP program covered limited dental and prescrip-
tions, providing coverage similar to what someone on Ontario 
Works or welfare would receive. When cuts were announced, they 
removed both refugee claimants and privately-sponsored refugees 
from coverage. People would only be covered if their health con-
cerns were a danger to public safety or public health (homicidal, 
infectious), but if they affected just their own health (suicidal), 
they weren’t covered. This has created a huge gap for acute care: 
for example, there was a very high-profile case in Toronto where 
a refugee claimant from Latin America was faced with near-blind-
ness from a retinal detachment. An ophthalmologist at St. Michael’s 
Hospital ignored the new policy on a humanitarian basis and per-
formed the surgery for free—the hospital had no choice but to ab-
sorb the costs of the surgery because they couldn’t see somebody go 
blind for the lack of a simple procedure. 
Why do you think it’s important for students to be aware of glob-
al health issues?
Western definitely has a really rich history of social justice 
within the medical school, and I would encourage students to be-
come involved in its initiatives. When I was a medical student, I 
sought out those opportunities—for example, I was on the edito-
rial staff of the University Of Western Ontario Medical Journal 
(UWOMJ) and discovered that writing was a good way to help en-
courage global health initiatives. 
As a student, it is really important to know about global health 
issues in order to have awareness right at the beginning. We used to 
think health was purely biological, and then we began to think of it 
as being biological, psychological and social. We are now aware that 
it involves the entire ecosystem and that awareness is so important 
from the beginning because you begin to see the interconnected-
ness of things when you study disease processes. When I worked 
at the South Riverdale Community Health Center in Toronto, Dr 
Michael Rachlis, who was the New Democratic Party (NDP) health 
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critic, noticed that a number of children within that community 
had disabilities. After the investigations revealed the cause to be en-
vironmental lead poisoning, he took a much more global approach 
and recognized that he needed to step out of the confines of the ex-
amining room and look at what was happening in the environment. 
He mobilized the community to stop Canada Metal from pumping 
lead into the environment and causing the poisoning. If we begin 
with that framework as a student, it really gives us the awareness 
needed to engage in health advocacy.
Have you had any international health-related experiences? Do 
physicians need to leave Canada to be involved in global health?
As a medical student, I went to India for 4 months and spent 
some time in New Delhi and some rural areas surrounding Delhi. 
I learned from that international elective the importance of mar-
ginalization—I spent a lot of time doing obstetrics and gynecology 
and recognized the gender inequity that was part of the developing 
world. That carries forward here: when immigrant women come to 
Canada, they end up having experienced that marginalization but 
also face the additional pressures that come with immigration.
I think we have so many opportunities to do work locally. Al-
though a lot of my patients are refugees or new immigrants, it’s al-
ways nice to seek out an additional project outside of practice that 
encompasses other interests. The Newcomer Health Project does 
that for me. One of my colleagues runs a clinic within the home-
less shelter once a week, while another colleague is the physician 
representative to the school board and works on lunch programs in 
schools with children living in poverty. Engaging in one project out-
side of regular work is how my colleagues and I seek involvement in 
global health locally.
What are some of the concerns of global health today? How have 
things changed?
Sustainability and the environment are two huge challenges for 
global health in the future, and equity is an issue both internation-
ally and at home. We also need to look at the bigger picture. Global 
health is a trans-discipline environment; a big challenge is learning 
to work with not just other health care disciplines but also with so-
cial scientists and policy makers. 
Global health has changed a lot for the better. For one thing 
the world has become a much smaller place, so that sense of “us 
and them” doesn’t exist now. The model has changed; we recognize 
now that we’re all in this together, that we share a responsibility 
for the inequities of the world. There’s instead a greater sense of 
“we’re all in the same boat”—we’re much more aware of the ethics 
of global health. 
Anything else you want to share?
For students, engagement in global health can be daunting. 
What I would say is to do some soul-searching and find one project 
that speaks to your heart. Through the course of your work life, find 
one longitudinal project and keep it on the back burner of your day-
to-day work life.
Dr Bhooma Bhayana received the 2013 College of Family Physicians 
of Canada (CFPC) Geeta Gupta Award for Equity and Diversity. The 
award recognizes the achievements of an outstanding family phy-
sician CFPC member (or a team) in active practice who has shown 
leadership and advanced awareness working in his or her practice and 
community to foster respect and understanding of a minority or un-
derserviced population.
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thinking on your feet
mrs malik
A physician working at a local emergency department is sum-
moned to see a patient who is complaining of a worsening cough 
and fever.  At triage blood pressure was 118/70 mmHg and heart rate 
was 72 bpm; the nurse also recorded a temperature of 38.5°C and the 
patient seemed to be in distress with an elevated respiratory rate of 
22 breaths per minute. Mrs Malik presented to the emergency room 
with a 4-week history of worsening cough, fever and night sweats ac-
companied by hemoptysis.  The triage nurse reports that this patient 
does not speak English very well and will need an interpreter. 
Mrs Malik is a 56-year-old woman of Pakistani descent; she ar-
rived to Canada six months ago as a refugee seeking to start a new 
life for her family and herself.  Mrs Malik does not have a family 
doctor, which is why she presented to the emergency department 
when she was feeling ill.  She lives with her husband, Khan (age 58), 
her children, Ahmed (age 18) and Ayesha (age 17), and her mother, 
Asia (age 79). Mrs Malik does not have a significant medical histo-
ry; she had two normal vaginal deliveries for her children and no 
other hospitalizations.  Currently she is on no medication and has 
no known allergies.
Physical examination reveals a productive cough, with bibasilar 
rales in addition to lymph node enlargement in the distribution of the 
posterior cervical chain.  Mrs Malik seems unwell, as there are signs 
of respiratory distress.  The physician decides to start the diagnostic 
journey with a chest x-ray, along with a complete blood count and cell 
differential.  The x-ray reveals diffuse pulmonary infiltrates and the 
blood test shows leukocytosis.  Although necessary, these preliminary 
tests only broaden the differential diagnosis for this patient’s condi-
tion. Based on these results the pulmonary condition can be infec-
tious, such as pneumonia or tuberculosis; malignant, either a primary 
lung cancer or a metastasis from a secondary tumor; or autoimmune, 
such as polyangiitis granulomatosis.  All of these conditions are very 
serious and can result in serious morbidity, so the physician decides 
to tackle this daunting differential by further working up the patient. 
tuberculosis status of refugees and newcomers
The incidence of tuberculosis (TB) is on a steady decline in Can-
ada over the past 3 decades, but there is disparity among some of the 
populations living within Canada.  These populations include the Ab-
original populations and populations of refugees and newcomers.  Ev-
ery year Canada takes on approximately 10  000 refugees from areas 
of political, cultural and environmental distress.1 These refugees are 
exposed to various pathogens that increase their risk of contracting 
infectious diseases. Although predeparture screening programs exist, 
they may not be rigorous or comprehensive due to the conditions and 
circumstances of regions from which refugees originate. Further, in-
ternational rules encourage the resettlement of all refugees regardless 
of medical illness. This is in contrast to other migrant categories in 
which individuals may be restricted from immigration to Canada if 
they have serious health morbidities. In addition despite the existence 
of rigorous screening for government-assisted refugees, there is no 
corresponding system for claimants.
One key morbidity relevant to migrants is infection with Myco-
bacterium tuberculosis.  Most of these infections are discovered in the 
inactive phase, meaning the patient is a carrier of the illness and is 
able to convert into the active state and become symptomatic.  The 
incidence rate of active TB among the refugee population is 20 times 
that of the Canadian-born non-Aboriginal population, which is cur-
rently 5 cases per 100 000 persons.2 Individuals with a latent TB 
infection comprise 30 to 50% of newcomers, which works out to 1.5 
million people in Canada who are carriers of the disease and at risk for 
developing the active infection and passing it on.3
what confers risk upon newcomer populations?
Many factors influence the risk that a newcomer incurs for TB 
infection while in Canada.  The most important predictors of risk in-
clude country of origin, migratory category, other comorbidities and 
the time since arrival in Canada. Of the 9.2 million cases of active TB 
worldwide, most are clustered in endemic areas such sub-Saharan Af-
rica and Asia in which the individuals are more likely to be exposed 
to the tuberculin inoculum.4 Further, whether individuals identify as 
immigrants or refugees is an indicator of their risk for infection; this 
is due to the fact that refugees come from regions in which TB is of 
higher prevalence and from relatively poor living circumstances.4 In 
addition, individuals with comorbidities, particularly HIV infection, 
that reduce the body’s ability to fight off infection are at a greater risk. 
Lastly, time since arrival also correlates with infectivity; individuals 
who are not diagnosed with TB within the first 5 years of arrival are at 
lower risk of developing the infection.  The risk is highest within the 
first year and dramatically decreases thereafter.4,5 Therefore, based 
on these criteria, individuals can be stratified into risk groups.
Table 1: Quick Facts: Incidence of Tuberculosis in Countries of  
Canadian Immigrantsa
country incidence rate (per 100 000 people)
Phillipines 265
Pakistan 231
India 176
China 73
a Adapted from Citizen and Immigration Canada and World Health Organization.12,13
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Aware of the aforementioned risks, the physician decides to elic-
it a comprehensive history from Mrs Malik and her family. Mrs Malik 
tells the physician that many years ago as a child she had a lung infec-
tion that lasted for a very long time but eventually resolved.  During 
her predeparture medical examination she had a positive TB skin 
test; however, her chest x-ray was negative.  Currently, she lives in a 
one-bedroom apartment along with family.  She does not complain 
of any other symptoms and says that she has been healthy in the past 
with no other health issues.  She does not smoke or consume alcohol. 
Lab tests for renal function and autoimmune antibodies are negative. 
This information and the preliminary tests together suggest an infec-
tious process with a high index of suspicion of TB. 
Table 3: Quick Facts: Latent Tuberculosis Infection (LTBI)a
•	 Affects one third of world’s population.
•	 Individuals are asymptomatic and noninfectious but are at risk of 
developing active disease and becoming infectious.
•	 Risk of reactivation increases with immunosuppression, malnutrition, 
diabetes and alcohol abuse.
•	 Individuals with LTBI should undergo prophylactic treatment  
with isoniazid. 
a Adapted from World Health Organization.14
screening at risk populations
Attempts are made to screen refugee populations for infective 
diseases such as TB; however, despite these efforts many individuals 
migrate to Canada and become ill with TB.  All individuals desiring 
entry into Canada, including refugees, are screened with a chest x-ray. 
A sputum culture is indicated in those individuals with a positive 
screening chest x-ray.3,6 Individuals with an active infection must be 
treated and provide proof of treatment and recovery.  Most individuals 
screened with a chest x-ray fall within the category of latent TB in-
fection.  These individuals should report to a health care professional 
within 30 days of their arrival in Canada;6 but many individuals with 
latent TB never make it to a postarrival health care check-up and thus 
they end up falling through the cracks.  In addition, despite the efforts 
put into the predeparture screening, it is not as efficient as it needs to 
be, as it identifies only 1% of active TB cases and 3 to 5% of latent cases 
while refugees and newcomers account for 65% of TB cases in Can-
ada.3,7 Furthermore, many issues arise with postlanding management 
of individuals who are identified as being carriers of the infection.  In-
dividuals often fail to complete screening and report for medical eval-
uation for a positive screen test.  Health practitioners also come short 
when it comes to prescribing chemoprophylaxis and this is often fol-
lowed by poor compliance due to lack of symptoms and long duration 
of treatment.8 These pitfalls uncover inadequacies in the health care 
system in terms of providing health care to newcomers.
Mrs Malik is confirmed to have an active TB infection based 
on a positive stain sputum smear for Mycobacterium tuberculosis, 
which revealed acid-fast bacilli.  Along with the history of previous 
infection, the present symptoms and investigations, the physician 
confirms the diagnosis of active TB infection and proceeds with the 
treatment of Mrs Malik.  The patient is isolated and admitted to the 
respirology service for rigorous treatment.  Since this is an active case 
of TB, the emergency physician goes on to report the case to public 
health.  Furthermore, Mrs Malik is asked to provide a list of contacts.
management of new cases of tuberculosis in the 
refugee population
Treatment regimes and protocols have been developed and test-
ed for both latent and active TB.  Ideally individuals are identified in 
the latent infection phase and treated before reactivation.  Current-
ly the management for latent TB is a 9-month course of isoniazid.9 
Many randomized control trials have shown that chemoprophylaxis 
is more effective than placebo at preventing reactivation.10 A baseline 
evaluation of hepatic function must be done before initiation of treat-
ment since there is a risk of hepatic toxicity.11 A large barrier to che-
moprophylaxis is monitoring and ensuring patient compliance to the 
9-month regimen, which diminishes the efficacy of risk reduction.  In 
patients with active TB, the treatment course is much more demand-
ing as it involves 2 phases of treatment and multiple drugs over an ex-
tended duration of time.  In addition, during the treatment the patient 
needs to be kept in isolation to prevent propagation of the infection.  
Treatment of active TB includes an initial treatment with isonia-
zid, rifampin, pyrazinamide and ethambutol for a minimum duration 
of 8 weeks.9 Thereafter a continuation phase is started with isoniazid 
and rifampin for 26 weeks.  At the end of this treatment protocol, in-
vestigations such as cultures and x-rays need to demonstrate resolu-
tion of the infection. If resolution of the infection is not achieved, the 
physician will need to investigate as to whether this due to patient 
compliance issues or a drug-resistant infection. During treatment, he-
patic function should be monitored for any signs of toxicity.9 Manage-
ment of an active TB infection extends beyond the infected patient, 
as the event must be reported to public health.  Furthermore, due to 
the potential for transmission, contact tracing must be performed and 
contacts must be assessed and treated accordingly. This emphasizes 
the importance of early detection and chemoprophylaxis.
Canada is internationally recognized for its efforts in resettling 
refugees from all over the world. Many resources are allocated to en-
sure the success of the resettlement process. Often times, however, 
the predeparture process is preferentially resourced, leaving the post-
landing procedures without enough support. More awareness needs 
to be drawn to the heightened TB risk that our refugees are burdened 
with such that our physicians aren’t left “thinking on their feet”.
Table 3: Quick Facts: World Health Organization Recommendations on Tuber-
culosis Control Using Direct Observed Therapy (DOT)a
five components of dot
1. Political commitment with increased sustained financing
2. Case detection through quality assured bacteriology
3. Standardized treatment with supervision and patient support
4. An effective drug supply and management system
5. Monitoring and evaluation system and impact measurement
a Adapted from World Health Organization.14
thinking on your feet
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Be careful eating the local catch
An unusual case of mass scombroid poisoning in deployed forces in Indonesia
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introduction
Our case begins in a setting far removed from a typical North 
American hospital. It begins in Sumatra, Indonesia during earth-
quake recovery efforts in November, 2009. An Australian Defence 
Force medical team was deployed to help with the recovery efforts. 
After a successful mission providing relief, the deployed forces start-
ed to pack up their supplies and prepared to leave in the next few 
days. Shortly after dinnertime, however, one of the staff members 
presented to the medical staff in the mobile centre with generalized 
urticaria.1
initial considerations & response
Acute urticaria, a red itchy rash often referred to as hives, can 
have multiple etiologies. The most common causes are related to 
allergic reactions to foods, medications, or insect bites. Although 
more common in pediatric patients, infections can also lead to acute 
urticaria in adults. Rarer causes for adult urticarial include vascu-
litis and systemic lupus erythematosus, but these usually present 
with other physical symptoms.2
Due to the limited resources of the mobile centre and acute 
time frame of presentation, full testing could not be completed, so 
these rarer causes could not be completely ruled out. Based on the 
presentation of acute urticaria in isolation, a tentative diagnosis of 
an allergic reaction was given for the staff member and a search 
was done to elucidate the trigger for the reaction. Intramuscular 
adrenaline, oral promethazine, ranitidine, and intravenous steroids 
were administered. Before a trigger for the allergic reaction could 
be determined, however, another patient presented with a similar 
clinical picture.
additional cases
A second staff member presented with truncal urticaria, oral 
angioedema, hoarseness, and dysphagia approximately 20 min-
utes after the first patient had sought assistance.1 The addition of 
a second case to this clinical picture so soon after the initial case, 
while not inconsistent with an allergic reaction, raised doubts 
about whether a hypersensitivity reaction was truly the underlying 
cause.3 This second staff member mentioned that some others were 
also feeling unwell and experiencing similar symptoms. Over an-
other 20 minutes, 5 other staff members presented with varying de-
grees of urticaria, erythema, abdominal pain, and dysphagia. Given 
the setting—a mobile Australian Defence Force base in Indonesia—
this massive influx of new patients had several important implica-
tions. Due to the small size of the mobile centre and because many 
of the supplies had been packed, the treatment capacity of the cen-
tre was quickly overwhelmed by this sudden influx of patients. The 
supply of adrenaline and steroids was quickly exhausted, and there 
were only two patient monitors available. To further compound 
this resource shortage, one of the senior nurses also began to show 
symptoms. Panic set in among the staff as they wondered about the 
identity of the trigger for these reactions. The search for a causative 
agent was intensified. The patients had some similar exposures that 
were investigated, such as a wet muddy field and a lightly damaged 
building they had visited previously; however, no causative agent 
could be found. Ingested toxins were also considered but none were 
identified at this point.1
response & resolution
As no causative agent could be found, evacuation of the pa-
tients to a nearby offshore ship, the HMAS (Her Majesty’s Aus-
tralian Ship) Kanimbla, was requested. Medical staff on board the 
ship were informed of the situation and proceeded to conduct an 
internet search for possible causative agents. That search suggest-
ed the possibility of scombroid poisoning, a type of food poisoning 
associated with the consumption of fish. Further investigation re-
vealed all affected patients had eaten 3 servings or more of a lo-
cally acquired white meat dish believed to contain fish. This dish 
was referred to as “ficken” by the Australian Defence Force medical 
team as a joke because of the inability to ascertain exactly what kind 
of meat it was made from.  Upon questioning, other staff person-
nel who ingested smaller quantities of ficken reported some mild 
nausea and abdominal cramping. Based on these findings, a clini-
cal diagnosis of scombroid toxicity was made and all patients were 
successfully treated with intramuscular adrenaline, ranitidine, in-
travenous steroids, and oral promethazine. Additional supplies and 
personnel were dispatched from the HMAS Kanimbla to assist with 
treatment.1
scombroid poisoning
Scombroid food poisoning generally occurs when histidine-rich 
fish are consumed after improper storage.1 Fish of the Scombroi-
dei genus, such as tuna or mackerel, are the most common culprits, 
though other species fish have been implicated.1,4,5 The pathogene-
sis of scombroid poisoning is believed to be the conversion of histidine 
to histamine by bacteria, often gram-negative enteric bacilli such as 
Escherichia coli.1,6 The conversion process involves a decarboxylase 
enzyme, and occurs primarily when the fish is stored above 16°C.1 
Other biogenic amines may play a role, though their effects have yet 
to be established.1,5 Nevertheless, the result is, in effect, poisoning by 
an overabundance of histamine.1,3-5 Symptoms vary, but are extreme-
ly similar to an immediate IgE-mediated hypersensitivity reaction 
and can include flushing, widespread urticaria, edema, nausea, and 
bronchospasm.1,3,7 Initial onset of symptoms often occurs within one 
hour of consumption of the affected food, and can persist for up to 36 
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hours.1,4 Scombroid food poisoning can be extremely difficult to di-
agnose, due to the similarity of its symptoms to those of an allergic re-
action and its atypical method of action. While scombroid poisoning 
does involve bacterial spoiling of food, unlike more common forms 
of food poisoning, killing the responsible bacteria does not eliminate 
the toxin—high heat does not destroy histamine, so properly cooked 
fish can still cause scombroid poisoning.1,5 Furthermore, there may 
be no obvious signs of spoiling, as histamine does not change the odor 
or appearance of the fish.4
Diagnosis of scombroid poisoning can often be made clinically, 
though additional testing may be used for confirmation.1,6,7 The tim-
ing of symptoms, with an initial presentation shortly after consump-
tion, is an important factor but may not help distinguish scombroid 
from a standard allergic reaction.5 The keys to clinical diagnosis are 
the absence of a history with allergies and the simultaneous onset 
of symptoms with other patients.1,5-7 Blood histamine levels will 
be highly elevated initially, with a significant reduction within 24 
hours.6 Levels of histamine or histamine byproducts in the urine may 
also be elevated.6 If a sample is available, direct testing of the ingest-
ed fish for histamine concentrations can also be diagnostic.3,6 In our 
case, the situation precluded use of supplementary diagnostic tools, 
and the diagnosis was made clinically.1
Treatment for scombroid poisoning is supportive in nature.1,7 
Fast-acting antihistamines, fluids, and antipyretic agents should be 
used to control symptoms as needed.1,4,7 Promethazine, the antihis-
tamine used in this case, is an older, first generation sedating anti-
histamine that is not frequently used in Canada; diphenhydramine 
is traditionally the emergency antihistamine of choice. In extreme 
cases, where closure of the airway becomes a concern, administra-
tion of adrenaline may be necessary.1,7 Use of corticosteroids has 
been reported and was used in this case, although their value has 
been questioned.1,3,4,7 Patients should recover within 36 hours as the 
excess histamine is cleared from the body, though careful monitor-
ing is required to ensure symptoms are responding appropriately to 
medication.1,3-5
conclusion
This case illustrates some of the challenges of practicing medi-
cine in a more remote area with limited supplies and resources, and 
where backup cannot be accessed quickly. Treatment of patients 
was initially hindered both because of a supply shortage and be-
cause health care providers who would normally provide treatment 
were among the patients. Assistance eventually was provided by the 
HMAS Kanimbla, but there was a 4-hour delay between the request 
for assistance and help arriving. The lack of medical and human re-
sources made the search for the causative agent more difficult as well. 
This is highlighted by the fact that foodborne illness was considered 
but initially ruled out due to inadequate investigation. Moreover, ig-
norance about the regional cuisine—in this case, the mystery meat in 
ficken—proved to be a barrier in establishing a diagnosis, as the com-
mon history of fish consumption was revealed only after scombroid 
poisoning was proposed as a possibility, despite a concerted effort to 
find a connection between patients. This highlights how practicing 
medicine in unfamiliar locations or cultures can result in missing 
knowledge, and therefore lead to an incomplete history.
However, this case also demonstrates the value of open lines of 
communication. The ability to consult outside support and subse-
quently to call in additional resources was instrumental in achiev-
ing a successful response to this unique medical crisis.1 The insights 
gained from this case are relevant to medicine practiced in situations 
with limited resources and in situations where information is limit-
ed due to a culture gap. These lessons are increasingly important as 
medicine continues to be practiced from a more global perspective.
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